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Preface 
 
 
Patients undergoing major vascular surgery are at increased risk for 
perioperative and long-term cardiac complications. Despite recent advances in 
perioperative and long-term care, the 30-day cardiac death rate of major vascular 
surgery varies between 3-6%, and the cardiac event rate during long-term follow-up 
between 30%-40% (1, 2). The high incidence of perioperative and late cardiac 
complications in these patients is associated with a higher prevalence of coronary 
artery disease. Thirty-six percent of patients undergoing abdominal aortic aneurysm 
repair and in about 28% of patients undergoing infrainguinal revascularization have 
severe coronary artery disease, and only 6% of all vascular patients have normal 
coronary arteries (3). 
Cardiac risk factors and noninvasive diagnostic tests for coronary artery 
disease may help to identify high-risk patients before major vascular surgery. 
Subsequent pharmacological therapy may be utilized in these high-risk individuals in 
order to lower their risk during and after vascular surgery. Based on the findings 
described in this thesis we are now able to classify patients as low-, intermediate-, or 
high-risk ones for cardiac complications after vascular surgery. These risk 
stratification tools include patients' baseline characteristics, dobutamine stress 
echocardiography, 12-lead electrocardiography and cardiac troponin T. Identification 
of these patients may help clinicians to introduce clinical measures including regular 
outpatient clinic visits, medication use or further evaluation and treatment of coronary 
artery disease. 
 
Outline of the thesis 
 
Part 1: Preoperative risk evaluation-clinical risk factors 
 Cardiac risk stratification begins with the assessment of clinical history and 
knowledge of the surgical and anesthesiological procedures being performed. A 
number of risk indices have been developed over the past decades (4-6), and 
baseline characteristics identified associated with adverse cardiac outcome. In this 
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part of the thesis after summarizing the current knowledge about cardiac risk factors 
and cardiac risk assessment in patients undergoing major vascular surgery we 
further explore the additional value of risk factors such as decreased creatinine 
clearance, aortic stenosis and elevated troponin T levels. Moreover, the performance 
of two previously developed risk models are tested, and a new risk model based on 
baseline characteristics, type of surgery and electrocardiographic abnormalities is 
proposed. 
 Chapter 1 is a systematic review describing the pathophysiology of 
perioperative cardiac complications, cardiac risk assessment and risk reduction 
strategies of patients undergoing major vascular surgery. This comprehensive review 
puts emphasis on preoperative cardiac evaluation of patients undergoing major 
vascular surgery, which could provide clinicians with an opportunity to reduce 
perioperative and late cardiac risk through prevention and optimal treatment of 
myocardial ischemia. 
 In chapter 2, a comparison is made between serum creatinine and creatinine 
clearance for the prediction of postoperative mortality in 852 patients undergoing 
major vascular surgery. 
 In chapter 3, the incidence of perioperative events in patients with aortic 
stenosis undergoing noncardiac surgery is assessed. The elevated risk of 
perioperative complication for 108 patients with moderate to severe aortic stenosis is 
compared to patients without aortic stenosis. 
 Subsequently, in chapter 4 the safety of performing dobutamine stress 
echocardiography in patients with aortic stenosis is described. Our own experience is 
evaluated on the basis of 75 patients with aortic stenosis who underwent either low-
dose dobutamine stress echocardiography for the assessment of the severity of 
aortic stenosis, or a full-dose protocol for diagnostic purposes. 
In chapter 5, we assessed the long-term prognostic value of asymptomatic 
cardiac troponin T elevations in patients after successful major vascular surgery. 
Long-term mortality rates were compared for patients with and without cardiac 
troponin T elevations. 
 In chapter 6, a validation of two risk models for perioperative mortality in 
patients undergoing abdominal aortic aneurysm surgery is described. Using data of 
361 patients who underwent abdominal aortic aneurysm surgery we compare the 
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performance of the so-called Leiden and the United Kingdom Small Aneurysm Trial 
prediction models. 
 Next, in chapter 7 we evaluate the perioperative cardiovascular mortality in 
108,613 noncardiac surgical procedures based on the Erasmus Medical Center 
experience during 1991-2000. A risk model is described based on clinical risk factors, 
type of surgery and resting electrocardiographic abnormalities. 
 
Part 2: Preoperative cardiac risk evaluation-noninvasive testing 
 Patient with multiple cardiac risk factors are often referred for further cardiac 
risk assessment by noninvasive testing prior to major vascular surgery. The 
prognostic accuracy of individual noninvasive diagnostic tests has been extensively 
evaluated over recent decades (6, 7). However, it is still uncertain, which of these 
tests shows the best prognostic accuracy. In this part of the thesis we evaluate the 
additional prognostic value of dobutamine stress echocardiography for the decision 
on the timing of abdominal aortic surgery; and to evaluate the comparative 
performance of different noninvasive tests for predicting perioperative cardiac risk. 
 In chapter 8, we propose an individualized clinical approach to perform early 
surgery for abdominal aortic aneurysm or institute ultrasonographic surveillance 
based on the combination of cardiac risk factors and dobutamine stress 
echocardiography. 
 In chapter 9, we compare the additional prognostic value of dobutamine stress 
echocardiography, dipyridamole stress echocardiography and dipyridamole 
myocardial perfusion scintigraphy on clinical risk factors in 2,204 consecutive 
patients undergoing major vascular surgery. 
 Subsequently, chapter 10 describes a meta-analysis of the prognostic 
accuracy of six diagnostic tests for predicting perioperative cardiac risk in patients 
undergoing major vascular surgery. 
 
Part 3: Perioperative pharmacological therapy 
 The efficacy of perioperative pharmacological therapy, especially beta-blocker 
therapy for the reduction of perioperative cardiac mortality and nonfatal myocardial 
infarction is well documented (8, 9). However, despite the beneficial effect of beta-
blocker therapy, beta-blockers are currently underused in the perioperative setting 
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(10, 11). Additionally, data is emerging that other pharmacological agents, such as 
statins may have possible cardioprotective effect via influence on the vascular 
function, which results in coronary plaque stabilization and subsequently in 
preventing coronary plaque rupture leading to myocardial infarction (12). In this part 
of the thesis, we evaluate the reasons for withholding beta-blockers in the 
perioperative setting, beneficial effect of statin use for the reduction of perioperative 
mortality, and the combined effect of beta-blocker and statin use. 
 In chapter 11, reasons that may play role to withhold beta-blockers from high-
risk patients with coronary artery disease are evaluated. 
 Next, in chapter 12 for the first time we describe that statins are associated 
with a reduced incidence of perioperative mortality in patients undergoing major 
noncardiac vascular surgery. In this case-control study, 160 patients who died during 
hospital stay are compared with 320 controls with regard to cardiac risk factors and 
statin use. 
 Subsequently, chapter 13 evaluates whether statins and beta-blocker are 
independently associated with a reduced incidence of perioperative mortality in 
patients undergoing abdominal aortic aneurysm surgery. 
 
Part 4: Long-term pharmacological therapy 
 After major vascular surgery patients still remain at increased risk of cardiac-
related death and nonfatal myocardial infarction (1, 2). The frequency of late cardiac 
morbidity reflects the high prevalence of underlying coronary artery disease (3). The 
optimal approach to the diagnosis and long-term management of coronary artery 
disease, which is often stable or asymptomatic in patients who underwent major 
vascular surgery, is unclear. This part of the thesis assesses the diagnostic utility of 
dobutamine stress echocardiography, and the cardioprotective effect of beta-blocker 
and statin use. 
In chapter 14, the optimal long-term cardiac management after major vascular 
surgery is described based on follow-up data of the Dutch Echocardiographic 
Cardiac Risk Evaluation Applying Stress Echocardiography study. The follow-up 
study was conducted in 1,286 patients who survived surgery for at least 30 days. The 
role of beta-blocker therapy, clinical characteristics, and dobutamine stress 
echocardiography is evaluated for the sake of long-term cardiac management. 
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Finally, chapter 15 deals with long-term statin use after major vascular 
surgery. A follow-up study describes the effects of statin use, and the additional 
effect of beta-blocker use on the incidence of all-cause and long-term cardiovascular 
mortality in patients who have undergone successful abdominal aortic aneurysm 
surgery. 
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Abstract 
 
Background: Cardiac troponin T (cTnT) is a sensitive and specific marker for 
myocardial injury, but elevations of cTnT without clinical evidence of ischemia and 
persistent or new electrocardiographic (ECG) abnormalities are common in patients 
undergoing major vascular surgery. We explored the long-term prognostic value of 
cTnT levels in these patients. 
Methods: A follow-up study was conducted between 1996-2000 in 393 patients who 
underwent successful aortic or infrainguinal vascular surgery and routine sampling of 
cTnT. Patients were followed until May 2003 (median of four years [25th-75th 
percentile, 2.8-5.3 years]. Total creatine kinase (CK), CK-MB, and cTnT were 
routinely screened in all patients, and included sampling after surgery and the 
mornings of postoperative days 2, 3 and 7. Electrocardiograms were also routinely 
evaluated for sign of ischemia. An elevated cTnT was defined as serum 
concentrations >0.1 ng/mL in any of these samples. All-cause mortality was 
evaluated during long-term follow-up. 
Results: Eighty patients (20%) had late death. The incidence of all-cause mortality 
(41% vs. 17%; p<0.001) was significantly higher in patients with an elevated cTnT 
level compared to patients with normal cTnT. After adjustment for baseline clinical 
characteristics, the association between an elevated cTnT level and increased 
incidence of all-cause mortality (adjusted hazard ratio, 1.9; 95% CI, 1.1-3.1) 
persisted. Elevated cTnT had significant prognostic value in patients with and without 
renal dysfunction, abnormal levels of CK-MB, and in patients with transient ECG 
abnormalities. 
Conclusions: Elevated cTnT levels are associated with an increased incidence of 
all-cause mortality in patients undergoing major vascular surgery. 
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Introduction 
 In patients undergoing major vascular surgery myocardial ischemia is the most 
common cause of perioperative and late morbidity and mortality.1-4 However, 
symptoms of myocardial ischemia may be masked by perioperative use of sedative 
and analgesic drugs, and detection of perioperative myocardial ischemia may be 
hampered by false positive elevations of MB creatine kinase levels attributed to 
skeletal muscle injury occurring during surgery.5 Recently, cardiac troponins have 
emerged as new risk stratification tools for prediction of perioperative and short-term 
cardiac complications. Cardiac troponins (T or I) are highly sensitive and specific 
markers for myocardial injury.6 It has been shown that routine surveillance for cardiac 
troponins can be useful for identifying patients without clinical evidence of myocardial 
ischemia who are at increased risk of perioperative myocardial infarction and death.5, 
7-9 However, these studies are limited by relatively small numbers of patients, mixture 
of surgical populations, and by a short duration of follow-up. Accordingly, the aim of 
the present study was to explore the long-term prognostic value of cardiac troponin T 
(cTnT) levels after successful major vascular surgery in patients without clinical 
evidence of ischemia or new electrocardiographic changes consistent with ischemia. 
 
Methods 
 
Study population 
 We retrospectively reviewed the hospital electronic database for all patients 
who underwent major vascular surgery between May 1996 and December 2000 at 
the Erasmus Medical Center, Rotterdam, the Netherlands. This database holds 
information on demographic data, clinical records, and information on the 
perioperative course of all patients. During this period, the hospital protocol 
recommended serial blood sampling for cardiac enzymes and electrocardiograms 
(day 2, 3 and 7 or discharge) in patients undergoing major vascular surgery. As a 
result of this protocol serial sampling of cardiac enzymes and electrocardiograms 
were taken in 402 patients who underwent major elective vascular surgery. Of these 
402 patients, nine patients with elevated cTnT died or developed nonfatal myocardial 
infarction after surgery and subsequently were excluded from the analyses. The 
remaining 393 patients who survived at least 30 days after surgery 
formed the base of the present study.
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Measurement of CK, CK-MB, and cardiac troponin T 
Total creatine kinase and creatine kinase MB activities were measured until 
December 1998 (n=242 patients) by means of a N-acetylcysteine-activated optimised 
ultraviolet test (Merck; Darmstadt, Germany). Creatine kinase MB activity was 
determined by immunoinhibition. After December 1998, a mass assay for CK and 
CK-MB, utilizing a monoclonal antibody, was performed on the Roche/Hitachi 747 
analyser. The upper levels of the reference intervals of CK was 190 IU/L, and for CK-
MB activity above 24 IU/L, or the CK-MB activity fraction exceeding 6% of total CK.  
 Cardiac troponin T during the entire study period was measured qualitatively 
using a whole blood rapid test (TropT version 2, Roche Diagnostics, Mannheim, 
Germany).10 The cut-off value for an abnormal cTnT test result was >0.1 ng/mL. 
 
Data collection 
The computerized hospital database, medical files, nurses reports, surgical 
records, postoperative charts, discharge letters and records of the outpatient clinic 
visits were manually screened to collect information on the presence of clinical risk 
factors and chronic cardiac medication use. Medical records were screened for the 
following clinical risk factors including age, gender, current or prior stable angina, 
previous MI, congestive heart failure, chronic pulmonary disease, renal dysfunction, 
diabetes mellitus, stroke, and hypertension. Additionally, postoperative 12-lead 
electrocardiograms were evaluated for abnormalities consistent with sign of 
ischemia, myocardial infarction or conduction abnormalities. 
 
Follow-up 
 In May 2003 a follow-up was performed of all 393 patients who survived major 
vascular surgery for at least 30 days. The primary endpoint chosen for the present 
study was all-case mortality in order to avoid misclassification among cardiac, 
arrhythmic and noncardiac mortality. Information about patients’ vital status was 
requested by approaching the Office of Civil Registry. For patients who died at the 
Erasmus MC during follow-up, hospital records and autopsy results were retrieved 
and reviewed. For patients who died outside of Erasmus MC, general practitioners 
were approached to ascertain the cause of death. If no autopsy was performed, 
medical information provided by general practitioners was used to ascertain the  
cause of death.
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Statistical analysis 
 Dichotomous variables were compared by means of Fisher’s exact test, and 
continuous variables were compared by means of Kruskal-Wallis test. The Kaplan-
Meier method was used to evaluate the prognostic value of cTnT with respect to 
event-free survival. Differences in survival curves were compared by the log-rank 
test. Univariable Cox proportional hazard regression models were used to assess the 
independent association between cTnT, baseline clinical characteristics, and all-
cause mortality. In order to avoid model over-fitting we applied a clinical risk model 
(3) that was developed elsewhere, and the clinical risk assessment was summarized 
in 1 index variable. Multivariable regression models were constructed by backward 
stepwise deletion of the least significant characteristics. Hazard ratios (HRs) and 
corresponding 95% confidence intervals (CIs) are reported. For all tests, a P value 
was <0.05 considered significant. All analyses were performed using SPSS statistical 
software (SPSS Inc., Chicago, Illinois, version 11.0). 
 
Results 
 
Patient characteristics 
 The characteristics of the study population are described in Table 1. Fourteen 
percent of patients had elevated (>0.1 ng/mL) cTnT levels postoperatively. Patients 
with abnormal cTnT levels were older, more often had a history of angina pectoris, 
renal dysfunction, and more often underwent acute or elective abdominal aortic 
aneurysm repair than patients with normal cTnT levels (Table 1). Furthermore, Ca-
channel blocker and nitrate use, and elevated serum creatinine levels, abnormal 
elevations of postoperative creatine kinase and creatine kinase MB isoenzyme, and 
abnormal electrocardiograms were also more often observed in patients with 
abnormal levels of cTnT compared to patients with normal levels of cTnT (Table 1). 
  62 
Table 1. Baseline characteristics 
 Cardiac Troponin T Level  
Characteristics Abnormal* 
n=54, (%) 
Normal 
n=339, (%) 
P-value† 
Demographics 
Age >70 years 
Male sex 
 
34 (63) 
45 (83) 
 
154 (45) 
268 (79) 
 
0.02 
0.60 
Medical history 
Current stable or history of angina 
pectoris 
Previous myocardial infarction 
Congestive heart failure 
Diabetes mellitus 
Prior cerebrovascular accident 
Renal dysfunction 
Chronic pulmonary disease 
Hypertension 
Prior CABG 
Prior PTCA 
 
23 (43) 
 
22 (41) 
4 (7) 
6 (11) 
6 (11) 
16 (30) 
15 (28) 
23 (43) 
6 (11) 
1 (2) 
 
65 (19) 
 
102 (30) 
14 (4) 
46 (14) 
45 (13) 
42 (12) 
68 (20) 
132 (39) 
34 (10) 
14 (4) 
 
0.001 
 
0.15 
0.29 
0.83 
0.82 
0.003 
0.21 
0.65 
0.81 
0.70 
Type of surgery 
Acute abdominal aortic repair 
Thoracoabdominal aneurysm repair 
Abdominal aortic aneurysm repair 
Aortoiliac repair 
Infrainguinal bypass 
 
6 (11) 
2 (4) 
25 (46) 
9 (17) 
12 (22) 
 
11 (3) 
12 (4) 
131 (39) 
51 (15) 
134 (40) 
0.04 
 
 
 
 
 
Chronic cardiac medication 
ACE inhibitors 
Aspirin 
ß-blockers 
Ca-channel blockers 
Nitrates 
Statins 
 
24 (44) 
25 (46) 
30 (56) 
20 (37) 
21 (39) 
21 (39) 
 
127 (38) 
133 (39) 
169 (50) 
59 (17) 
49 (15) 
137 (40) 
 
0.37 
0.37 
0.47 
0.02 
<0.001 
0.88 
Electrocardiogram 
Left ventricular hypertrophy 
Q waves consistent with previous 
myocardial infarction 
ST-segment changes consistent with 
ischemia 
 
14 (26) 
12 (23) 
 
15 (28) 
 
 
59 (14) 
38 (11) 
 
45 (13) 
 
 
0.14 
0.03 
 
0.007 
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Table 1. Baseline characteristics [cont] 
 Cardiac Troponin T Level  
Characteristics Abnormal* 
n=54 (%) 
Normal 
n=339 (%) 
P-value† 
Laboratory findings 
Serum creatinine, mmol/L [median, 
IQR] 
Abnormal levels of creatine kinase 
Abnormal levels of creatine kinase, MB 
isoenzyme 
 
98.5 [80.8-143.5] 
 
30 (56) 
9 (17) 
 
82 [67-104] 
 
108 (32) 
22 (7) 
 
<0.001 
 
0.001 
0.03 
*All data are presented as number (percentage) unless otherwise indicated; IQR, indicates 
interquartile range; CABG, coronary artery bypass surgery; PTCA, percutaneous transluminal 
coronary angioplasty; For definition of risk factors see “Methods” section. 
†Fisher exact 2-sided test, independent t-test or Kruskal-Wallis test 
 
Follow-up 
 The median follow-up was 4.3 years (25th-75th percentile, 2.8-5.3 years). 
Eighty (20%) patients died during follow-up, among whom 49 died of cardiac causes. 
The cause of non-cardiac death was respiratory insufficiency in 10, cancer 10, sepsis 
secondary to infected prosthetic grafts 7, renal failure 2 and other causes in 2. 
Additionally, five (1.3%) patients had late coronary revascularization because of 
progression of angina pectoris, six patients suffered non-fatal cerebrovascular 
accident, and there were five patients who developed symptoms of congestive heart 
failure. 
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Relation between abnormal cTnT levels and long-term outcome 
 Survival of patients with abnormal and normal cTnT levels is shown in Figure 
1. 
 
Figure 1. Kaplan-Meier estimates of all-cause mortality according to normal and 
elevated levels of cardiac troponin T.  
 
 
Abnormal levels of cTnT were associated with a significant increased risk of all-cause 
mortality in univariable analysis. Compared with patients with normal cTnT levels, 
patients with abnormal cTnT levels had a more than two-fold increase in risk of all-
cause mortality (crude HR, 2.4; 95%CI, 1.5-4.0). Other variables that were 
associated with all-cause mortality in our dataset included chronic pulmonary disease 
and type of surgery. Patients who underwent acute abdominal aortic repair, 
thoracoabdominal and abdominal aortic aneurysm repairs had relatively high long-
term mortality rates (Table 2).  
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Table 2. Univariable predictors and estimated risk of long-term all-cause mortality 
Variables*  Unadjusted 
 Patients who 
died, n (%) 
HR (95% CI) P-value 
Demographics 
Age>70 years 
Male gender 
 
46 (24.5) 
64 (20.4) 
 
1.6 (1.0-2.4) 
1.1 (0.6-1.8) 
 
0.05 
0.82 
Medical history 
Current stable or history of angina pectoris 
Previous myocardial infarction 
Congestive heart failure 
Diabetes mellitus 
Prior cerebrovascular accident 
Renal dysfunction 
Chronic pulmonary disease 
Hypertension 
Prior CABG 
Previous PTCA 
 
24 (27.3) 
30 (24.2) 
6 (33.3) 
11 (21.2) 
14 (27.5) 
13 (22.4) 
26 (31.3) 
33 (21.2) 
10 (25.0) 
1 (6.7) 
 
1.3 (0.8-2.2) 
1.3 (0.8-2.1) 
1.9 (0.8-4.3) 
1.1 (0.6-2.2) 
1.6 (0.9-3.0) 
1.3 (0.7-2.3) 
1.7 (1.1-2.8) 
1.0 (0.7-1.6) 
1.1 (0.5-2.1) 
0.4 (0.1-2.6) 
 
0.20 
0.22 
0.15 
0.67 
0.10 
0.43 
0.02 
0.90 
0.85 
0.31 
Type of surgery, compared with infrainguinal 
bypass 
Acute abdominal aortic repair 
Thoracoabdominal aneurysm surgery 
Abdominal aortic aneurysm repair 
Aortoiliac repair 
 
20 (13.7) 
6 (35.3) 
7 (50.0) 
40 (25.6) 
7 (11.7) 
 
 
3.8 (1.5-9.6) 
6.5 (2.7-15.5) 
1.9 (1.1-3.3) 
0.8 (0.3-1.8) 
 
 
0.004 
<0.001 
0.01 
0.60 
Chronic cardiac medication 
ACE-inhibitors 
Aspirin 
ß-blockers 
Ca-channel blockers 
Nitrates 
Statins 
 
30 (20.0) 
23 (14.6) 
34 (17.1) 
19 (24.1) 
20 (28.6) 
14 (8.9) 
 
0.9 (0.6-1.4) 
0.6 (0.4-0.9) 
0.7 (0.4-1.0) 
1.0 (0.6-1.7) 
1.5 (0.9-2.6) 
0.3 (0.2-0.5) 
 
0.70 
0.03 
0.05 
0.95 
0.10 
<0.001 
Electrocardiogram 
Left ventricular hypertrophy 
Q waves consistent with previous MI 
ST segment changes consistent with 
ischemia 
 
20 (27.4) 
13 (26.0) 
17 (28.3) 
 
 
1.7 (1.0-2.8) 
1.3 (0.7-2.7) 
1.6 (0.9-2.8) 
 
 
0.05 
0.40 
0.08 
 
Laboratory findings 
Abnormal CK-MB/CK index 
Abnormal cardiac troponin T 
 
8 (25.8) 
22 (40.7) 
 
1.6 (0.7-3.4) 
2.4 (1.5-4.0) 
 
0.20 
0.001 
*For definition of risk factors and laboratory findings see “Methods” section; HR, hazard ratio; CI, 
confidence interval
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In contrast, aspirin, beta-blocker and statin use were associated with reduced all-
cause mortality. Additionally, no association was observed between abnormal CK-
MB levels and long-term mortality. The association between increased cTnT levels 
and the incidence of all-cause mortality persisted in multivariable analyses after 
correcting for other clinical risk factors, and electrocardiographic changes consistent 
with myocardial ischemia (Table 3). 
 
Table 3. Multivariable predictors and estimated risk of long-term all-cause mortality 
(N=393) 
Variables* Adjusted 
 HR (95% CI) P-value 
Abnormal cardiac Troponin T 
ST segment changes consistent with ischemia 
Risk factors†, compared with no risk factors 
>3 
1 to 2 
Type of surgery, compared with infrainguinal bypass 
Acute abdominal aortic repair 
Thoracoabdominal aneurysm surgery 
Abdominal aortic aneurysm repair 
Aortoiliac repair 
Chronic cardiac medication 
Statins 
ß-blockers 
Aspirin 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1.9 (1.1-3.1) 
1.8 (1.0-3.1) 
 
5.5 (1.8-16.5) 
2.8 (1.0-8.1) 
 
2.4 (0.8-7.0) 
8.5 (3.4-20.1) 
2.4 (1.4-4.3) 
1.3 (0.5-3.2) 
 
0.3 (0.2-0.5) 
0.5 (0.3-0.8) 
0.6 (0.3-0.9) 
0.02 
0.05 
 
0.002 
0.05 
 
0.1 
<0.001 
0.003 
0.6 
 
<0.001 
0.004 
0.04 
*For definition of variables see “Methods” section; HR, hazard ratio; CI, confidence interval 
†Risk score was composed by assigning 1 point to each of the following characteristics: age>70 
years, angina pectoris, prior myocardial infarction, heart failure, prior cerebrovascular event, diabetes 
mellitus, renal dysfunction and chronic pulmonary disease 
 
In separate analyses we also studied the prognostic value of cTnT levels in different 
subgroups of patients. There were no significant differences observed in the 
prognostic value of abnormal cTnT levels in subgroup of patients with renal 
dysfunction, elevated levels of CK-MB or in patients with ischemic ST-segment 
changes on electrocardiogram (Table 4). 
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Table 4. Prognostic value of abnormal cTnT levels according to subgroups of 
patients* 
 Abnormal 
cTnT 
Normal 
cTnT 
HR (95% CI) Abnormal 
cTnT 
Normal 
cTnT 
HR (95% CI) P 
value† 
 Normal renal function Renal dysfunction  
Total 
Death 
38 
18 (47.4%) 
297 
49 (16.5%) 
 
3.0 (1.8-5.2) 
16 
4 (25%) 
42 
9 (21.4%) 
 
0.9 (0.3-3.3) 
 
0.08 
 Normal CK-MB levels Abnormal CK-MB levels  
Total 
Death 
44 
19 (43.2%) 
304 
50 (16.4%) 
 
2.6 (1.6-4.5) 
9 
3 (33.4%) 
22 
5 (22.7%) 
 
1.4 (0.3-5.9) 
 
0.23 
 No ST segment changes ST segment changes  
Total 
Death 
37 
14 (37.8%) 
294 
48 (16.3%) 
 
2.1 (1.1-3.8) 
15 
7 (46.7%) 
45 
10 (22.3%) 
 
2.1 (0.8-5.4) 
 
0.98 
*Numbers may not add up to 393 due to missing data; HR, hazard ratio; CI, confidence interval 
†P value for interaction represents a level of statistical evidence for heterogeneity in the prognostic value of cTnT in subgroup of 
patients with renal dysfunction, abnormal levels of CK-MB and ST segment changes on electrocardiograms consistent with 
ischemia 
 
Prognostic value of cTnT levels according to cardiac risk factors 
Based on the number of cardiac risk factors and the presence of abnormal 
cTnT levels the incidence of all-cause mortality was estimated. If patients had a risk 
index of 0 no patients had abnormal cTnT levels and the incidence of all-cause 
mortality was 6.1% in patients with normal cTnT (Figure 2). In contrast, patients with 
a risk index of 1 to 2 and 3 or more risk factors and with abnormal cTnT levels were 
at substantially higher risk of adverse perioperative outcome compared to patients 
with normal cTnT levels. 
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Figure 2. Incidence of all-cause mortality according to cardiac risk factors and 
normal and elevated levels of cardiac troponin T. 
 
Results are based on the number of clinical risk factors (age>70 years, current angina, prior 
myocardial infarction, heart failure, prior cerebrovascular event, diabetes mellitus, renal insufficiency 
and pulmonary disease), and normal and abnormal levels of cardiac troponin T. 
 
Discussion 
 Asymptomatic cardiac troponin T elevations were associated with an almost 
two-fold increased risk of long-term mortality in patients undergoing successful major 
vascular surgery, independent of the presence of risk factors for coronary artery 
disease, renal dysfunction, cardiac medication use, elevated CK-MB levels and ST-
changes consistent with myocardial ischemia. 
 These findings are consistent with the results of previous studies on cardiac 
troponins as markers of myocardial injury in noncardiac surgery setting. Several 
investigations have shown that abnormal levels of cardiac troponins identify patients 
at increased risk of perioperative and short-term cardiac complications.5, 7-9 Lopez-
Jimenez et al.9, showed that abnormal levels of cTnT in patients undergoing 
noncardiac surgery was associated with a more than four-fold increased risk of 
cardiac events during a six-month follow-up period. Kim et al. later confirmed these 
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findings7, in 229 patients who underwent serial measurements of cardiac troponin I 
levels after vascular surgery. Twenty-eight (12%) patients had abnormal 
postoperative cardiac troponin I levels, which was associated with a six-fold 
increased risk of six-month mortality. In a more recent study similar to our findings, 
Landesberg et al, also found a positive association between abnormal levels of 
cardiac troponin I after vascular surgery and all-cause mortality during on average of 
two an half years of follow-up.11 
 Patients undergoing noncardiac surgery with or at high risk of coronary artery 
disease have an incidence of perioperative myocardial ischemia exceeding 40% with 
an associated nine-fold increased risk for cardiac death and myocardial infarction.12, 
13 Patients with events related to myocardial ischemia and surviving the perioperative 
period still remain at high risk for long-term cardiac complications.14 In this regard, 
patients undergoing major vascular surgery are particularly at very high risk for 
perioperative and long-term mortality and morbidity related to myocardial ischemia.2, 
15-17 Detection of myocardial ischemia during and after major vascular surgery could 
be difficult as a result of altered pain perception, false positive elevations of CK-MB 
levels or due to presence of pre-existing electrocardiographic abnormalities.18 
Cardiac troponins, on the other hand may help to identify patients at increased risk 
for perioperative and short-term adverse events. It contrast, it has been observed 
that many patients without cardiac complications or symptoms related to myocardial 
ischemia may have elevated cTnT levels 8, raising the question whether or not these 
abnormal values are false positive results, or indeed evidence of asymptomatic 
myocardial injury. The findings of our study provide evidence that asymptomatic 
patients with elevated cTnT levels remain also at increased risk for long-term 
mortality. 
In earlier reports it was described that renal dysfunction may interfere with the 
prognostic value of cTnT because of its clearance may be decreased. In contrast, 
Aviles et al.19, showed that cTnT levels predicted short-term prognosis in acute 
coronary syndrome patients regardless of the presence or absence of renal 
dysfunction. Consistent with these findings we found that abnormal cTnT levels 
independently predicted long-term all-cause mortality regardless of renal dysfunction. 
Similarly to previous studies the prognostic value of abnormal cTnT levels was 
superior to that of CK-MB elevations. In fact, patients with abnormal cTnT levels 
experienced adverse long-term mortality more often than patients with elevated CK-
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MB levels.8, 9, 20-22 These data are consistent with findings for surgical and 
nonsurgical populations indicating that abnormal cTnT levels is a marker for 
myocardial injury, even if that myocardial injury is not sufficient to cause CK-MB 
release and clinical symptoms. Furthermore, the findings of our study indicate that 
abnormal levels of cTnT independently predicted long-term mortality in patients with 
and without ECG abnormalities consistent with myocardial ischemia. These results 
are consistent with the hypothesis that elevated cTnT levels in these patients may 
reflect a degree of myocardial ischemia, which is not sufficient to cause ECG 
abnormalities that would be detected by routine 12-lead ECG recordings.9 These 
findings indicate that cTnT may further facilitate identification of high-risk patients. 
There are no clinical studies about the long-term optimal treatment strategy to 
patients with asymptomatic cardiac troponin T elevations after successful major 
vascular surgery. However, previous reports of medical patients show that a 
relationship between elevated levels of cardiac troponin and incidence of cardiac 
complications may help to guide risk stratification practices, and as a screening test, 
cardiac troponins have been shown to improve clinical management and 
subsequently improve survival of patients presenting to emergency room with acute 
chest pain.23 Recently, a marked reduction in adverse cardiac events were reported 
among patients with elevated cardiac troponins and acute coronary syndromes if 
they were randomized to an early invasive treatment.24 Our data suggest that 
inclusion of cTnT in the long-term management of patients with asymptomatic 
elevations of cTnT may have clinical utility for developing optimal treatment 
strategies. 
Several limitations of this study should be considered when interpreting the 
results. Since this study was observational, adverse outcome events could potentially 
have been missed. However, we used all cause specific mortality data as the primary 
outcome measure for this study. Additionally, during the study period a qualitative 
test was used for detecting elevated levels of cTnT, which did not allow us to 
investigate the relation between different cTnT levels and incidence of cardiac 
complications. 
In conclusion, abnormal levels of cTnT after successful major vascular surgery 
are associated with a higher incidence of long-term all-cause mortality, and provide 
additional prognostic information to clinical risk factors and CK-MB levels. Clinical 
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studies are required to determine the most optimal approach and management for 
patients with abnormal cTnT levels to improve their long-term outcome. 
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Abstract 
 
Background: The classical preoperative cardiovascular risk evaluation scores for 
non-cardiac surgery date from the 1970s and 1980s, and are based on relatively 
small samples and a few outcome events. 
Methods and Results: We studied the 108,613 non-cardiac surgical procedures that 
were performed in 75,581 adult patients during 1991-2000 in the Erasmus MC, 
Rotterdam, the Netherlands. Consistent with clinical practice the surgical procedure 
was taken as unit of analysis. Perioperative mortality occurred in 1,877 cases (1.7%), 
of which 543 were due to cardiovascular complications (0.5% of the population; 29% 
of deaths). The incidence of cardiovascular mortality was higher in men than in 
women (0.7 versus 0.3%). There were no significant changes in cardiovascular 
mortality over time in either men or in women. Advanced age, male gender, type of 
surgery, diabetes mellitus, hypertension, ischemic heart disease, heart failure, stroke, 
and renal failure were identified as important clinical risk factors for cardiovascular 
death. An resting ECG within 90 days prior to surgery was available in 28,457 cases. 
An abnormal ECG was associated with increased perioperative cardiovascular 
mortality. Based on these results, a score was developed to estimate an individual 
patient’s risk of cardiovascular death in relation to a specific surgical procedure, 
which had excellent discriminative ability (c-index in the range 0.809 to 0.870). 
Conclusions: The combination of clinical characteristics and ECG measurements 
identify non-cardiac surgical patients at risk of perioperative cardiovascular death. 
The developed multivariable risk models showed excellent ability to discriminate 
between patients at low, intermediate and high risk of cardiovascular complications, 
and can readily be applied in routine perioperative management. These risk 
prediction models can also be used to identify target populations for the development 
of risk reduction strategies. 
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Introduction 
 
Patients undergoing major non-cardiac surgery are at significant risk of 
cardiovascular morbidity and mortality. Perioperative myocardial infarction is the 
most frequent complication in this respect. Evidence exists that, as in non-surgical 
settings, coronary plaque rupture leading to thrombus formation and subsequent 
vessel occlusion, is the predominant mechanism.[1,2] The clinical importance of 
perioperative cardiovascular complications is well recognized, and numerous 
investigators have described the relationship between patient characteristics and the 
risk of adverse cardiovascular outcome.[3-10] The multivariable cardiovascular risk 
indices developed by Goldman, Detsky and Eagle are most frequently quoted in this 
respect.[3,7,10] However, most studies evaluating cardiovascular risk in a general 
surgical population date from the 1970s and 1980s. Since then, there have been 
potentially significant advances in anaesthesia, surgery and postoperative care. The 
impact of these developments on the incidence and lethality of cardiovascular 
complications and the predictive value of established risk factors is yet unknown. 
Furthermore, the classical investigations of unselected surgical patients are based on 
relatively small samples (the largest series, from 1987, consists of 2,609 patients) 
and a few outcome events.[5,9]. Consequently, important risk factors may have been 
missed, due to a lack of statistical power. More recent studies have focused on 
patients undergoing specific types of surgery, such as thoracic, orthopedic, or 
vascular.[8,11,12]. These facts prompted us to develop a cardiovascular risk 
assessment score based on recent data and applicable to patients undergoing a 
broad spectrum of non-cardiac surgical procedures. Accordingly, we studied the 
108,593 patients who underwent non-cardiac surgery in our center from 1991 to 
2000. We examined trends in the incidence of fatal perioperative cardiovascular 
complications over time, and studied the relationship between clinical and 
electrocardiographic variables and fatal cardiovascular outcome. Our results may 
facilitate routine perioperative clinical management, and the design of future studies 
evaluating potential risk reduction strategies. 
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Methods 
 
Hospital setting, procedures and patients 
The Erasmus Medical Center (MC) is a metropolitan university hospital, serving 
a population of approximately 3 million, in the south-western area of the Netherlands, 
which acts as a tertiary referral center for approximately 30 affiliated hospitals. In the 
Erasmus MC, between January 1, 1991 and December 31, 2000, 122,860 non-
cardiac surgical procedures were performed in patients above the age of 15 years. 
We excluded 14,267 unplanned procedures that were conducted within 30 days after 
an initial operation, and analyzed the perioperative course of the remaining 108,593 
cases. 
 The number of patients involved in this dataset amounts 75,581. Over the 10-
year observation period, 20,885 patients had multiple surgeries in the Erasmus MC. 
They were included as many times as they had surgeries. The median span between 
two successive procedures was 297 days (interquartile range 123 to 677 days; note 
that the minimum span was 31 days). Thus, we chose operation (and not patient) as 
unit of analysis, mainly for two reasons. Firstly, this is consistent with clinical practice, 
as the risk of perioperative complications is assessed in relation to a specific 
procedure. Secondly, this approach guarantees an optimal utilization of the available 
information. Dedicated statistical techniques were applied to account for potential 
dependence among observations (see paragraph on statistical analysis). 
 
Material 
For each patient undergoing surgery, a number of data-items are routinely (and 
prospectively) stored in the computerized hospital information system. First, the 
surgical techniques are classified by the treating physician according to a 
standardized national coding system, which was developed in co-operation with the 
National Health Service and medical insurance companies. This system is used for 
reimbursement and to record and monitor the experience of surgeons and surgical 
residents. Using this classification, we grouped surgical procedures into 14 
categories. 11,969 procedures (11.0 %) were classified into multiple categories. 
 Second, from written information that is provided by the General Practitioner, 
the referring physician, or the hospital physicians involved in perioperative care, each 
patient’s medical history is classified according to the ninth International 
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Classification of Diseases (ICD-9).[13] The classification, primarily used to develop 
national health statistics, is performed by dedicated administrative personnel who 
have completed in-depth training on registration of medical data. We recorded 
medical conditions that are considered potential determinants of perioperative 
cardiovascular outcome, including diabetes mellitus (ICD-9 250), 
hypercholesterolemia (ICD-9 272), hypertension (ICD-9 400), myocardial infarction 
(ICD-9 410, 411, and 412), angina pectoris (ICD-9 413 and 414), heart failure (ICD-9 
428), cerebrovascular accident (ICD-9 430), chronic obstructive pulmonary disease 
(ICD-9 496), and renal disease (ICD-9 580). 
 Third, according to hospital protocol, patients with established cardiovascular 
disease, or at increased risk of coronary disease based on their age and clinical 
characteristics, had a pre-operative resting 12-lead electrocardiogram (ECG) 
recorded at an outpatient cardiology clinic. Before October 1, 1994, Hewlett-Packard 
electrocardiographs were used and the ECG’s were computer-interpreted using an 
automated version of the Pipberger algorithm.[14] From October 1, 1994 onwards, 
the Portrait Electrocardiograph (Mortara Instrument, Inc.) with integrated 
interpretation software was used.[15] Because ECG-interpretation software generally 
has high diagnostic sensitivity but low specificity, the automated interpretation was 
subsequently evaluated, and if necessary changed, by an experienced cardiology 
resident. The corrected ECG interpretation was recorded in the hospital information 
system. An electrocardiographic evaluation within 90 days prior to surgery was 
available for 28,457 cases (26.2 %). 
 
Endpoint definition 
The hospital information system also contains data regarding each patient’s 
perioperative course. The vital status at hospital discharge was verified and 
documented for each patient. The occurrence of perioperative myocardial infarction 
was also reported, but the protocol did not mandate serial postoperative 
electrocardiograms, or blood sampling for determination of cardiac enzymes. 
Consequently, silent ischemic episodes and indistinct events might have been 
missed. A similar situation occurred with regard to stroke: Clinically apparent strokes 
were reported, but systematic neurological evaluation and CT-scanning was not 
performed. In view of these limitations, we chose cardiovascular death as the primary 
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endpoint of our analyses. Events were counted until hospital discharge or 30 days 
after surgery, whichever day came first. 
 To obtain the cause of death, two investigators (MDK, DP) reviewed all 
available medical records, surgical reports, laboratory values, ECGs and autopsy 
reports, and aimed to reach consensus. If consensus could not be reached, the 
opinion of a third, independent investigator (PN) was final. Cardiovascular death was 
defined as any death with a cardiovascular complication as the principal or 
secondary cause, and included deaths following myocardial infarction, cardiac 
arrhythmia, resuscitation, heart failure, or stroke. Non-cardiovascular death was 
defined as any death with a principal non-cardiovascular cause, including surgery-
related bleeding complications, cancer, trauma and infection. Sudden death in a 
previously stable patient was considered as cardiovascular. 
 
Statistical analysis 
Univariable and multivariable logistic regression analyses were applied to 
calculate crude and adjusted odds ratios (and 95 % confidence intervals) for the 
relationship between the selected clinical and electrocardiographic cardiovascular 
risk determinants, and the primary endpoint. We observed important differences in 
the incidence of the primary endpoint in relation to age, gender and type of surgery. 
Furthermore, during the 10-year study period, differences were observed in the 
annual volumes of several surgical procedures. Therefore, with regard to the results 
of univariable analysis, we decided to report odds ratios that are adjusted for age, 
gender, type of surgery and calendar year. All variables entered the multivariable 
stage irrespective the results of univariable analyses. The final multivariable model 
was then constructed by backward deletion of the least significant characteristics, 
while applying the Akaike information criterion (i.e. the applied threshold of 
significance depended on the degrees of freedom associated with the variable at 
hand; in case of one degree of freedom, then P≈0.157).[16] 
 In 1986 Liang and Zeger developed the method of generalized estimation 
equations (GEE) to determine regression model parameters - and corresponding 
standard errors - in datasets with correlated data when the outcome measure of 
interest is discrete (e.g. binary or count data).[17] Since our dataset involves patients 
with multiple operations, independence of observations could not be excluded 
beforehand. Therefore, to examine this phenomenon, all regression analyses were 
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first performed using conventional techniques, and then repeated using GEE, with 
‘patient’ as classification factor. No relevant differences were observed between the 
parameter estimates as determined according to both methodologies. Hence, we 
concluded that inter-observation correlation did not play a major role, if any, in our 
dataset. Still, we decided to present the results that are based on the GEE method. 
 The performance of the risk models was determined by the C-index, which 
indicates how well a model rank-orders patients with respect to their outcomes. The 
C-index ranges from 0.5 (no predictive value) to 1.0 (optimal performance).[18] In 
addition, the Hosmer-Lemeshow statistic for goodness of fit is presented. The 
predictive accuracy of the models was further evaluated by bootstrapping 
techniques.[19] One hundred bootstrap samples were drawn from the original 
dataset (with replacement) and the full modeling process, including the stepwise 
selection, was redone in every bootstrap sample. The models developed in the 
bootstrap samples were subsequently tested in the original dataset. This process 
provides a factor to correct for a possible overestimation (‘overoptimism’) of the 
predictive value by the c-index. 
 Based on the results obtained by these modeling strategies, a score was 
developed to estimate an individual patient’s risk of perioperative cardiovascular 
death. 
 
Results 
 
52,387 surgical procedures were performed in male patients. Orthopedic 
surgery (24 %), ENT-surgery (18 %), and abdominal surgery (16 %) were the most 
frequent (figure 1). Among the 56,206 procedures in women, gynecological surgery 
was most common (27 %), followed by orthopedic (18 %) and abdominal surgery (14 
%). As a result of a reallocation of patients between hospitals in our region, there 
were significant changes in the annual volumes of ophthalmic and gynecological 
procedures in the early 1990s (figure 2). Throughout the study period, the number of 
men and women undergoing orthopedic surgery gradually increased. The number of 
patients undergoing abdominal surgery decreased slightly over time. 
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Figure 1. Total number of surgical procedures in men (M) and women (F) that were 
performed at the Erasmus MC during 1991-2000 
 
The gray proportion of the bars indicate procedures that were classified into multiple categories 
 
 A total of 1,877 patients (1.7%) had perioperative death. A cardiovascular 
complication was the principal cause of death in 405 patients, and the secondary 
cause in another 138. Thus, 543 patients (0.5% of the population; 29% of deaths) 
had cardiovascular death. Patients in whom an autopsy report was available (326 
patients; 17% of deaths) were more often labeled as having cardiovascular death 
than patients in whom no such report was available (37 versus 27%; P-value 
<0.001). Infection was the most common non-cardiovascular cause of death (primary 
and secondary cause in 231 and 308 patients, respectively; 539 patients in all; 29% 
of deaths). 
  95
Figure 2. Time trends in the number of surgical procedures in men (closed circles) 
and women (open circles) 
 
 
In 1991 and 1992 over 2,500 gynecological procedures were performed, these data are represented 
by a square 
 
 Men were typically 7 years older than women (median age 51 years, 
interquartile range 34 to 65, and median age 44, interquartile range 32 to 62, 
respectively). The incidence of all-cause mortality, as well as cardiovascular mortality 
was higher in men than in women: 2.2 versus 1.3% (P-value <0.001), and 0.7 versus 
0.3% (P-value <0.001), respectively. As figure 3 demonstrates, during the study 
period, no systematic change in all-cause mortality was observed in men. In contrast, 
all-cause mortality in women increased significantly from 0.9% in 1991 to 1.5% in 
2000 (71% increase; P-value <0.001). There were no significant changes in 
cardiovascular mortality over time in either men or in women. After adjustment for 
age, calendar year and type of surgery, male gender was associated with a 31% 
increased risk in perioperative cardiovascular death (odds ratio 1.31, 95% CI 1.1 to 
1.6; P-value <0.001). 
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Figure 3. Time trends in the incidence of perioperative all-cause mortality (open 
circles) and cardiovascular mortality (closed circles) 
 Important differences in the incidence of perioperative cardiovascular death 
were observed in relation to type of surgery (table 1). Patients undergoing vascular 
surgery, especially those undergoing aortic surgery, had the highest cardiovascular 
mortality (1.8%), followed by patients undergoing neurosurgery (1.7%), renal 
transplant (1.1%) and pulmonary surgery (1.1%). Breast, dental, eye and gynecology 
surgery were associated with cardiovascular mortality rates below 0.1%. A scopic 
technique was applied in 15,318 patients (14%), who had a lower incidence of 
cardiovascular death than those undergoing open surgery (0.2 versus 0.6%; crude 
odds ratio 0.26 and 95% CI 0.2 to 0.4; P-value <0.001). The 774 patients (0.7%) who 
underwent emergency surgery had a higher incidence of cardiovascular death than 
patients undergoing non-emergency surgery (6.1 versus 0.5%; crude odds ratio 5.1 
and 95% CI 3.7 to 7.1; P-value <0.001). 
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 In univariable analyses, diabetes mellitus, hypercholesterolemia, 
hypertension, ischemic heart disease (CAD, i.e. myocardial infarction or angina 
pectoris), heart failure, stroke, and renal failure were associated with an increased 
risk of cardiovascular death (table 2). Diabetes, hypertension, established CAD, and 
heart failure remained significantly associated with adverse outcome after adjustment 
for multiple risk factors. Renal insufficiency was a strong outcome determinant in 
univariable analysis, but was not part of the multivariable regression model. It is 
noteworthy in this respect, that renal insufficiency was significantly correlated with 
hypertension and heart failure (Pearson correlation coefficient 0.36 and 0.23, 
respectively). Fifty-one percent of patients with renal failure had hypertension and 
21% had heart failure. In contrast, only 3% of patients without renal failure had 
hypertension, and only 1 % had heart failure. In combination with the mentioned 
clinical characteristics, age, gender, and type of surgery remained strong 
determinants of adverse perioperative cardiovascular outcome. Patients between 40 
and 50 years of age had a 2.3 times higher risk of cardiovascular death than those 
below 40, and the risk in octogenarians was over 20 times higher. The C-index for 
the cardiovascular mortality model based on age, gender, type of surgery, and 
clinical characteristics (as presented in table 2) was 0.870, reflecting good ability to 
discriminate between patients who did and did not have a fatal cardiovascular 
complication. The associated goodness of fit P-value was 0.54, indicating that the 
model adequately fitted with the data. After correction for overoptimism the C-index 
was 0.842, still reflecting good performance. 
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Table 2. Relation between demographic and clinical characteristics, and 
perioperative death 
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Crude odds ratios are adjusted for age, gender, type of surgery (when appropriate) and calendar year only. 
Multivariably adjusted odds ratios are only presented for the variables that remained in the multivariable model (see method 
section for the modeling strategy), and were adjusted for all the components of the multivariable model, and calendar year. 
Point estimates of odds ratios below 2.0 are presented with two decimals. 
† Class I include breast, dental, eye, gynecology, and urologic surgery; Class II include endocrine, orthopedic, and 
plastic/reconstructive surgery; Class III include abdominal, ENT, and pulmonary surgery; Class IV include neuro surgery, renal 
transplant, and vascular surgery 
 
 The 28,457 patients who underwent electrocardiographic evaluation within 90 
days prior to surgery had higher cardiovascular mortality than those who did not 
undergo such evaluation (0.7 versus 0.4%; P-value <0.001). This is a reflection of the 
applied hospital protocol that calls for a resting ECG in patients at suspected 
increased cardiovascular risk. Several electrocardiographic markers were 
independently associated with increased cardiovascular mortality, including atrial 
fibrillation, right bundle branch block (P-value 0.09), left ventricular hypertrophy, 
premature ventricular complexes, abnormal Q-waves, and ST-segment depression 
(table 3). Patients with a pacemaker were also at increased risk. The multivariable 
model that combined clinical data with ECG results had a better discriminating power 
than the clinical-data-only model (C-indices based on the 28,457 patients with 
complete ECG data 0.840 versus 0.812; P-value <0.001). The associated goodness 
of fit P-value was 0.55, and the overoptimism-corrected C-index was 0.809.
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Table 3. Relation between electrocardiographic characteristics and perioperative 
cardiovascular death 
Crude odds ratios are adjusted for age, gender, type of surgery and calendar year only. 
Multivariably adjusted odds ratios are only presented for the variables that remained in the multivariable model (see method 
section for the modelling strategy), and were adjusted for all the components of the multivariable model (which included clinical 
characteristics, see table 2), and calendar year. 
Point estimates of odds ratios below 2.0 are presented with two decimals. 
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 Figure 4 presents a simple risk score for perioperative cardiovascular mortality 
based on age, gender, type of surgery and clinical characteristics. The 56,757 
patients (52% of the population) with a score ≤40 points had a very low 
cardiovascular death rate (0.03%). In contrast, the 1,005 patients (1 % of the 
population) with a score >70 points had a very high cardiovascular death rate (7.2%). 
In the remaining 50,831 patients (47% of the population) with moderate to high 
cardiovascular mortality rates, the resting ECG (classified as normal versus 
abnormal) further discriminated between those at higher and lower risk. Still, patients 
in the highest risk categories with a normal resting ECG had cardiovascular mortality 
rates that were as high as 1.2 to 3.4%. 
 
Figure 4: A simple scheme to evaluate the risk of perioperative cardiovascular death 
in noncardiac surgery 
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Discussion 
 
In accordance with previous studies, our data showed that cardiovascular 
mortality is a major burden in patients undergoing non-cardiac surgery.[3-12] On 
average 7 out of 1,000 procedures in men and 3 out of 1,000 procedures in women 
had a fatal in-hospital outcome as a result of cardiovascular complications. In 
contrast, anaesthesia related mortality only occurs in approximately 1 out of 250,000 
procedures.[20] Interestingly, patients who underwent post-mortem examination were 
considerably more often classified as cardiovascular death than patients in whom no 
such examination was performed. This suggests that the incidence and impact of 
cardiovascular complications after non-cardiac surgery may be underestimated in 
clinical practice. 
 Guidelines of the American Heart Association (AHA) / American College of 
Cardiology (ACC) indicate advanced age as a minor predictor of cardiovascular 
risk.[21] In our data, however, perioperative cardiovascular mortality progressively 
increased with age. In fact, along with type of surgery, age was a much stronger 
outcome determinant than any other clinical characteristic. This finding may reflect 
the broad spectrum of surgical procedures that were included in our analysis as 
compared to other investigations,[3-12] and, along with that, a large diversity of 
patients with respect to age. Indeed, elderly patients often have (asymptomatic) 
coronary disease, which places them at an increased risk of perioperative 
cardiovascular complications. 
 At the other hand, the modest contribution of clinical characteristics, relative to 
age and type of surgery, might be the result of under-reporting. Details of the medical 
history were classified by administrative personnel on the basis of written information 
provided by health-care professionals. These employees are specifically instructed to 
avoid inappropriate over-diagnosis. As a result, important medical conditions might 
have been overlooked, and, consequently, the odds ratios for cardiovascular death 
related to these factors might have been underestimated. Also, we restricted our 
analyses to patients who underwent surgery. No information was included from 
patients who were screened, but did not undergo surgery because the risk was 
perceived as prohibitive. Obviously, exclusion of patients at risk of adverse 
cardiovascular outcome might have diluted estimates of relative risk. 
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 Resting 12-lead electrocardiography seemed to be of limited value in the 
sizeable group of patients (±50 % of the population studied) who are at low risk of 
perioperative cardiovascular mortality according to clinical characteristics and type of 
surgery. In contrast, the resting ECG provided useful additional prognostic 
information in patients with an intermediate risk. The resting ECG also contained 
prognostic information in high-risk patients, but failed to identify patients at sufficiently 
low risk to allow for surgery without additional cardiovascular evaluation. It should be 
noticed in this respect, that perioperative cardiac complications often occur in 
patients with clinically silent myocardial ischaemia,[22,23] which cannot be revealed 
by tools that evaluate the resting heart function. Instead, exercise or pharmacological 
stress testing is warranted.[24] However, perioperative resting ECG recordings are 
useful for detection of myocardial ischaemia (ST- and T-wave changes) and 
myocardial infarction (new Q-waves). 
 The identification of patients at risk of perioperative cardiovascular 
complications has considerably improved over the recent years. Also, effective risk-
reduction strategies have been defined for particular patient categories, such as 
those undergoing major vascular surgery.[25-27] In general, however, the 
investigations that successfully aimed at cardiovascular risk identification were not 
succeeded by investigations that aimed at systematic risk reduction. Hence, effective 
cardioprotective treatment strategies remain undefined for substantial portions of the 
non-cardiac surgery population. The development and implementation of such 
strategies for the entire surgical spectrum remains an important challenge for 
contemporary medicine. In that regard, it is noteworthy that the incidence of fatal 
perioperative cardiovascular complications at our centre did not decline during the 
10-year study period. Although information on large series of unselected surgical 
patients in comparable high-volume, tertiary referral centres is lacking, several 
observations in selected patients indicate that the Erasmus MC data are no 
exception.[11,28,29] 
 Of particular interest with regard to the development of risk-reduction 
strategies is the group of patients with an estimated perioperative cardiovascular 
mortality rate in the range 0.5 % to 3.0 %, comprising approximately 25 % of the 
study population. Current evidence suggest a potential role for exercise or 
pharmacological testing to identify the presence of stress-inducible myocardial 
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ischaemia.[12,21] According to the AHA / ACC guidelines, patients with inducible 
ischaemia should then undergo coronary angiography followed by coronary 
revascularisation.[21] Another option might be to proceed with surgery under 
effective pharmacological protection without preoperative evaluation of the heart 
function, since excessive myocardial ischaemia will likely be diagnosed in a minority 
of patients.[12] Promising results are observed in selected patients with beta-
blockers and inhibitors of 3-hydroxy-3-methylglutaryl coenzyme A (statins),[25-27] 
and properly sized randomised clinical trials are warranted to further evaluate the 
efficacy and safety of these agents. 
 We acknowledge that this investigation has some limitations because of the 
retrospective nature of the data. Particularly, the prognostic value of established risk 
factors that were not classified according to the ICD-9 classification, such as smoking 
and aortic valve stenosis, and the influence of cardiovascular medication, remained 
undefined. Furthermore, information on cardiovascular medication and interventions 
were available in the hospital medical records, but not in a systematic database. 
Consequently, it’s impact on perioperative outcome could not be assessed. 
Nevertheless, the developed multivariable risk models showed excellent ability to 
discriminate between patients at low, intermediate and high risk of cardiovascular 
complications, and can readily be applied in routine perioperative management. 
These risk prediction models can also be used to identify target populations for the 
development of risk reduction strategies. 
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Abstract 
 
Objective: To investigate the combined beneficial effect of statin and beta-blocker 
use on perioperative mortality and myocardial infarction (MI) in patients undergoing 
abdominal aortic aneurysm surgery (AAA). 
Background: Patients undergoing elective AAA-surgery identified by clinical risk 
factors and dobutamine stress echocardiography as being at high-risk often have 
considerable cardiac complication rate despite the use of beta-blockers. 
Methods: We studied 570 patients (mean age 69+9 years, 486 males) who 
underwent AAA-surgery between 1991-2001 at the Erasmus MC. Patients were 
evaluated for clinical risk factors (age>70 years, histories of MI, angina, diabetes 
mellitus, stroke, renal failure, heart failure and pulmonary disease), dobutamine 
stress echocardiography, statin and beta-blocker use. The main outcome was a 
composite of perioperative mortality and MI within 30 days of surgery. 
Results: Perioperative mortality or MI occurred in 51 (8.9%) patients. The incidence 
of the composite endpoint was significantly lower in statin users compared to 
nonusers (3.7% vs. 11.0%; crude odds ratio [OR]: 0.31, 95% confidence interval [CI]: 
0.13-0.74; p=0.01). After correcting for other covariates, the association between 
statin use and reduced incidence of the composite endpoint remained unchanged 
(OR: 0.24, 95% CI: 0.10-0.70; p=0.01). Beta-blocker use was also associated with a 
significant reduction in the composite endpoint (OR: 0.24, 95% CI: 0.11-0.54). 
Patients using a combination of statins and beta-blockers appeared to be at lower 
risk for the composite endpoint across multiple cardiac risk strata; particularly 
patients with 3 or more risk factors experienced significantly lower perioperative 
events. 
Conclusions: A combination of statin and beta-blocker use in patients with AAA-
surgery is associated with a reduced incidence of perioperative mortality and nonfatal 
MI particularly in patients at the highest risk. 
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Introduction 
Despite recent advances in perioperative care the 30-day mortality of elective 
abdominal aortic aneurysm (AAA) surgery still varies between 2.7% and 5.5% in 
selected series, up to 9% in population based studies (1, 2). In fact, cardiac related 
morbidity and mortality are one of the most frequently observed perioperative 
complications (3, 4). Thirty-six percent of patients undergoing AAA-surgery have 
severe coronary artery disease (CAD), whereas only 6% have normal coronary 
arteries (5, 6). Clinical risk assessment tools (7-9) have been successful risk 
stratifying patients, and thereby identifying those at particular benefit from beta-
blockers (10, 11). However, not all patients are equally protected by beta-blocker 
therapy. Patients identified by clinical risk factors and dobutamine stress 
echocardiography as being at high-risk often have a considerable cardiac 
complication rate despite the use of beta-blockers (12). Thus, additional treatment 
options are necessary to improve perioperative prognosis in high-risk patients 
undergoing major vascular surgery. 
Almost half of fatal postoperative myocardial infarction (MI) cases can be 
associated with coronary plaque rupture (13). The distribution of postoperative MIs, 
however, is not necessarily the same as hemodynamically critical coronary artery 
lesions (14). This may indicate the presence of CAD in numerous locations 
throughout the coronary tree, and the possibility that perioperative MI may result from 
plaque rupture and thrombosis at the site of a haemodynamically insignificant but 
unstable atherosclerotic plaque(s) (13). Lipid lowering therapy with HMG-Co-A 
reductase inhibitors (statins) has been shown to be beneficial in the primary and 
secondary prevention of cardiovascular disease, and the role of statins for the 
reduction of mortality and morbidity from CAD in patients at increased risk or with 
known CAD has also been established (15-17). In addition to being potent LDL-
lowering agents, statins may also attenuate plaque inflammation and influence 
plaque stability (18). These so called pleiotropic effects of statins can improve 
endothelial function and coagulation, and hence stabilize unstable atherosclerotic 
plaque(s) (19-21). We have previously shown that patients who underwent major 
vascular surgery and were statin users had a reduced risk of perioperative mortality 
as compared to nonusers (22). However, little is known about the combined effect of 
statin and beta-blocker use for the prevention of perioperative cardiac complications 
in different risk group categories. Thus the aim of the current study was to investigate 
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the relationship between the combined therapy of statin and beta-blocker use and 
perioperative complications across different cardiac risk categories in patients 
undergoing elective AAA-surgery. 
 
Methods 
Patients and study design 
The Erasmus Medical Center (MC) is an academic hospital in Rotterdam, the 
Netherlands, which acts as a tertiary referral center for approximately 30 affiliated 
hospitals. Between January 1991 and December 2001, a total of 75,581 patients 
over 18 years of age underwent 108,613 noncardiac surgical procedures at the 
Erasmus MC. Each surgical technique performed was classified by treating 
physicians according to a standardized national coding system that was developed in 
co-operation with the National Health Service and medical insurance companies. The 
type of surgery, demographic data, medical history, and information on the 
perioperative course of each patient was then systematically uploaded to an 
electronic database maintained by the Medical Information Department; via this 
database 570 patients were identified who underwent elective open infrarenal 
abdominal aortic surgery. 
 
Data collection and definition of risk factors 
 Along with clinical information, we also reviewed medical files and discharge 
letters for additional information on clinical risk factors, chronic cardiac medication 
use, intraoperative and perioperative hospital course, and cause and type of 
perioperative complications. Potential clinical determinants of perioperative mortality 
and MI were advanced age (>70 years), gender, current stable or prior angina 
pectoris, prior MI on the basis of medical history or a finding of pathologic Q waves 
on the electrocardiography, compensated congestive heart failure or a history of 
heart failure, renal dysfunction (serum creatinine >2 mg/dL [180 µmol/L]), current oral 
or insulin treatment for diabetes mellitus, a history of prior cerebrovascular accident 
including transient ischemic attack, hypertension, chronic pulmonary disease (forced 
expiratory volume in 1 s <75% of normal adjusted for age and gender) and smoking 
(23, 24). The average of two fasting levels of total cholesterol, LDL and HDL 
cholesterol levels were also included if they were measured three months prior to 
abdominal aortic surgery. Patients were defined as having elevated cholesterol levels 
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if total serum cholesterol level exceeded 212.7 mg/dL (5.5 mmol/L) or the LDL 
cholesterol level was higher than 135.3 mg/dL (3.5 mmol/L). In addition, data from 
the preoperative dobutamine stress echocardiography (DSE) were also collected if 
available. DSE was performed as previously described (3), and a positive test result 
for dobutamine stress echocardiography was considered if new wall-motion 
abnormalities occurred. In addition, the year of operation was also included given the 
influence of advances in perioperative care and surgical techniques.  
 
Chronic medication use 
According to routine procedure at Erasmus MC, patients visited the outpatient 
clinic at least three months prior to the planned major vascular surgery, and all 
patients were also screened for medication use in conjunction their medical history. 
During the study period additional cardiac medications including beta-blockers or 
statins were prescribed at the discretion of the attending physicians. Patients 
continued taking their cardiac medication also on the day of surgery, and oral 
medication use was resumed on day 1 after surgery. Based on institutional 
guidelines aspirin use was discontinued at least 10 days before elective AAA-
surgery. Two investigators (JK, DP), blinded to the patients’ perioperative outcome, 
reviewed medical records for medication use including aspirin, ACE-inhibitor, beta-
blocker and statin use. Chronic medication use was ascertained if medication use 
was documented at least one to three months prior to hospital admission for surgery. 
 
Definition of perioperative events 
As part of the routine postoperative management all patients were screened 
for cardiac enzyme elevations (creatine-kinase [CK], creatine-kinase MB [CK-MB], 
cardiac troponin T), and 12-lead electrocardiogram was made after major vascular 
surgery. Perioperative events were defined as a composite of all-cause mortality and 
MI occurring before discharge or within 30 days after surgery, whichever came first. 
The cause of perioperative death was retrieved from hospital records or autopsy 
results. MI was diagnosed according to our institutional laboratory protocol as a 
serum CK level of more than 190 U/L, and a CK-MB activity above 24 IU/L, or the 
CK-MB activity fraction exceeding 6% of total CK, or from 1996 as cardiac troponin T 
>0.1 ng/mL, and by new Q waves >1mm or >30 ms. 
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Statistical analysis 
Continuous variables were described as mean value + SD, and categorical 
variables as percent frequencies. Differences between patient subgroups were 
evaluated by using the t-test or chi-square test, as appropriate. The number of 
perioperative events in the study was relatively limited. Therefore, to avoid overfitting 
and to enable assessment of the relation between clinical risk factors and the 
composite of all-cause mortality and nonfatal MI, we used the Revised Cardiac Risk 
Index developed by Lee et al (9). Since the decision to prescribe statin or beta-
blocker therapy was not randomized, adjustments were made for baseline 
characteristics that may have influenced the decision to use either medication. 
Separate propensity scores were constructed using multiple logistic regression 
analyses. Baseline clinical characteristics that had an independent association with 
the decision to prescribe statins or beta-blockers (P=0.25) were included in the 
multivariable propensity score. Univariable logistic regression analyses were 
performed to study the relation between statin, beta-blockers, baseline clinical 
characteristics and the composite endpoint.  
Multivariable logistic regression analysis was also performed to study the 
association of statins and beta-blockers with the composite endpoint, with 
adjustments for baseline clinical characteristics and the two propensity scores. The 
discriminatory power of the multivariable regression model was quantified by the c-
index, which is identical to the area under the receiver operating characteristic curve; 
the c-index ranges from 0.5 (not predictive at all) to 1.0 (optimal performance). The 
performance of the multivariate regression model was further assessed with Hosmer-
Lemeshow goodness-of-fit test (25). Finally, to reveal a possible heterogeneity 
between statin or beta-blocker use and baseline clinical characteristics interaction 
terms were included in the models. Odds ratios (ORs) and corresponding 95% 
confidence intervals (CIs) are reported. All analyses were performed using SPSS 
statistical software (SPSS Inc., Chicago, Illinois, version 11.0).
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Results 
Patient characteristics 
Patient characteristics according to statin use are described in Table 1. Statin 
users were more often younger, women, and had a higher body mass index than 
nonusers. Furthermore, statin users had a higher prevalence of cardiovascular 
disease; a higher prevalence of renal dysfunction, more often underwent prior 
coronary revascularization, and had a lower prevalence of chronic pulmonary 
disease. There were no significant differences in total cholesterol, LDL- and HDL-
cholesterol levels between statin users compared to nonusers. Statin users more 
frequently used concomitant cardiac medications compared to statin nonusers. Of 
the 570 patients, 340 also underwent DSE one to three months prior to surgery. 
Patients who were statin users more often had a positive dobutamine stress 
echocardiography compared to nonusers. In 162 patients who were statin users the 
most frequently prescribed statins were simvastatin (71.6%), atorvastatin (14.8%), 
pravastatin (8.6%), cerivastatin (3.7%) and fluvastatin (1.2%), respectively. 
Perioperative mortality or MI occurred in 51 (8.9%) patients. Among these, there 
were 24 (47%) cardiovascular complications: 18 cardiac deaths, 4 nonfatal MIs and 
stroke in 2 patients. The most common non-vascular causes of death were septic 
complications (10 patients), respiratory insufficiency (9 patients) and intestinal 
necrosis (8 patients). Autopsy was performed in 28 (55%) patients. In patients who 
died and underwent postmortem examination the cause of death was more often 
classified as cardiac death (50%) than in patients who died but did not undergo 
autopsy (21%). 
  
 
158 
Table 1. Characteristics of the population 
Characteristics Patients who used 
statins*, 
N=162, (%) 
Patients who did not 
use statins, 
N=408, (%) 
P-
value† 
Demographics 
Age, years 
Age>70 years 
Male sex 
 
65.1+8.9 
61 (38) 
126 (78) 
 
70.5+8.6 
258 (63) 
360 (88) 
 
<0.001 
<0.001 
0.002 
Clinical variables 
Body mass index, kg/m2 
Current smoker 
Blood pressure, mm Hg 
Systolic 
Diastolic 
Cholesterol, mmol/L (mg/dL) 
Total 
LDL 
HDL 
 
25.8+3.5 
49 (32) 
 
146.7+20.3 
85.2+10.4 
 
5.6+1.2 (216+46.4) 
3.8+1.1 (146.9+42.5) 
1.1+0.5 (42.5+19.3) 
 
24.7+2.8 
130 (34) 
 
146.2+19.6 
86.0+11.0 
 
5.7+1.1 (220.4+42.5) 
3.8+0.6 (146.9+23.2) 
1.1+0.3 (42.5+11.6) 
 
0.002 
0.7 
 
0.8 
0.5 
 
0.9 
0.8 
0.8 
Medical history 
Current stable or history of 
angina pectoris 
Previous myocardial infarction 
Congestive heart failure 
Diabetes mellitus 
Prior cerebrovascular 
accident 
Renal insufficiency 
Pulmonary disease 
Hypertension 
‡Prior coronary 
revascularization 
 
47 (29) 
 
61 (38) 
8 (5) 
14 (9) 
21 (13) 
 
16 (10) 
27 (17) 
77 (47) 
24 (15) 
 
67 (16) 
 
78 (19) 
11 (3) 
22 (5) 
64 (16) 
 
15 (4) 
124 (30) 
200 (49) 
23 (6) 
 
0.001 
 
<0.001 
0.2 
0.2 
0.4 
 
0.007 
0.001 
0.8 
0.001 
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Table 1. Characteristics of the population [cont] 
Characteristics Patients who used 
statins*, 
N=162, (%) 
Patients who did not 
use statins, 
N=408, (%) 
P-value† 
Chronic cardiac medication 
ACE inhibitors 
Aspirin 
Beta-blockers 
 
69 (43) 
57 (36) 
103 (64) 
 
113 (28) 
72 (18) 
153 (38) 
 
0.001 
<0.001 
<0.001 
Dobutamine stress 
echocardiography 
New wall motion 
abnormalities 
No new wall motion 
abnormalities 
No test performed 
 
 
32 (20) 
 
75 (46) 
 
55 (34) 
 
 
49 (12) 
 
184 (45) 
 
175 (43) 
0.03 
*All data are presented as number (percentage) unless otherwise indicated; LDL, low-density 
lipoprotein; HDL, high-density lipoprotein; For definition of risk factors see “Methods” section; 
†Chi-square test 
‡It is a combination of prior coronary bypass graft surgery and percutaneous transluminal 
coronary angioplasty (only one procedure performed in each group) 
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Univariable analyses 
 A history of chronic pulmonary disease was the most important determinant of 
the composite endpoint (Table 2). Patients with a history of chronic pulmonary 
disease had an almost 5-fold increased risk of perioperative adverse events 
compared to patients without such history. Other significant univariable predictors of 
the composite endpoint were prior cerebrovascular accident, renal dysfunction, 
advanced age (>70 years) and previous MI. A positive DSE result was also a 
significant univariable predictor of perioperative events. Patients with a new wall-
motion abnormality during DSE had a significantly higher rate of perioperative 
mortality or nonfatal MI than patients without stress induced myocardial ischemia 
(17.3% versus 7.3%; P<0.001). Although there was a positive trend for improved 
perioperative outcome in patients who underwent previous coronary 
revascularization this association was not statistically significant (Table 2). There was 
no significant association between the year of operation and the composite endpoint 
(crude OR, 1.0, 95% CI, 0.9-1.1). In further univariable analyses, patients using 
statins or beta-blockers were at a significantly lower risk of perioperative adverse 
events compared to patients not using either of these medications. Compared with 
nonusers, patients who were using statins had a three-fold reduced risk- and patients 
using beta-blockers had a two-fold lower risk of the composite endpoint. There was a 
trend for aspirin and ACE inhibitors to reduce the incidence of perioperative events, 
however this association was not statistically significant. 
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Propensity to prescribe statins or beta-blockers 
 The propensity score for statin use showed that patients were more likely to 
be prescribed statins if they were younger, had a history of CAD or renal dysfunction, 
or had elevated total cholesterol levels (Table 3). The propensity score for beta-
blocker use showed that beta-blockers were more often used if patients were 
younger, or had a history of CAD, but were used less often in those with chronic 
pulmonary disease (Table 3). 
 
Effect of statin use according to the Revised Cardiac Risk Index 
Among the 246 patients with a risk score of one, there was one perioperative 
event observed in the 17.5% of patients using statins and four events (2%) in the 
remaining 203 patients (p=0.8). In the 242 patients with a risk score of two, 36% were 
using statins. One perioperative event (1.1%) occurred in this group, whereas 24 
(15.5%) events were observed in patients not using statins (p<0.001). Finally, in the 
82 patients with a risk score of 3 or more, 39% were statin users, and of those 12.5% 
had perioperative mortality or MI, while the event rate was 34% in those not using 
statins (p=0.02). There was no evidence of a differential effect of statin use in these 
subgroups of patients (P-value for interaction=0.96). 
 
Additional beneficial effect of statin use according to beta-blocker use  
Among 103 patients receiving a combination of beta-blockers and statins only 
two (1.9%) perioperative events occurred compared to 13 (8.5%) perioperative 
events in 153 patients using only beta-blockers (OR, 0.21, 95% CI, 0.05-0.96). In the 
314 patients who were beta-blocker nonusers, 18.7% were using statins. Four (6.8%) 
perioperative events occurred in this group, whereas approximately 50% more 
events occurred in patients who were nonusers (OR, 0.51, 95% CI, 0.17-1.50). Test 
for heterogeneity revealed no evidence for a differential effect of statin use in these 
patient categories (P-value for interaction=0.36). 
  
 
165 
Ta
bl
e 
3.
 O
dd
s 
ra
tio
s 
fo
r p
ro
pe
ns
ity
 s
co
re
s 
as
so
ci
at
ed
 w
ith
 p
re
sc
rip
tio
n 
of
 s
ta
tin
 o
r b
et
a-
bl
oc
ke
r u
se
 
C
ha
ra
ct
er
is
tic
s*
 
S
ta
tin
 u
se
 
ß-
bl
oc
ke
r u
se
 
 
R
eg
re
ss
io
n 
co
ef
fic
ie
nt
 
O
dd
s 
R
at
io
 (9
5%
 C
I) 
P-
va
lu
e 
R
eg
re
ss
io
n 
co
ef
fic
ie
nt
 
O
dd
s 
R
at
io
 (9
5%
 C
I) 
P
-v
al
ue
 
A
ge
 
M
al
e 
se
x 
C
ur
re
nt
 s
ta
bl
e 
or
 h
is
to
ry
 o
f 
an
gi
na
 p
ec
to
ris
 
P
re
vi
ou
s 
m
yo
ca
rd
ia
l i
nf
ar
ct
io
n 
C
on
ge
st
iv
e 
he
ar
t f
ai
lu
re
 
D
ia
be
te
s 
m
el
lit
us
 
P
rio
r c
er
eb
ro
va
sc
ul
ar
 a
cc
id
en
t 
R
en
al
 d
ys
fu
nc
tio
n 
C
hr
on
ic
 p
ul
m
on
ar
y 
di
se
as
e 
E
le
va
te
d 
to
ta
l c
ho
le
st
er
ol
 
-0
.0
7 
-0
.7
9 
0.
91
 
 
1.
14
 
0.
08
 
0.
62
 
…
 
1.
03
 
-0
.7
8 
1.
14
 
0.
93
 (0
.9
1-
0.
96
) 
0.
45
 (0
.2
6-
0.
78
) 
2.
50
 (1
.5
2-
4.
10
) 
 
3.
12
 (1
.9
6-
4.
96
) 
1.
08
 (0
.3
5-
3.
38
) 
1.
86
 (0
.8
6-
3.
90
) 
…
 
2.
80
 (1
.2
5-
6.
24
) 
0.
46
 (0
.2
7-
0.
78
) 
3.
12
 (2
.0
4-
4.
78
) 
<0
.0
01
 
0.
00
5 
<0
.0
01
 
 
<0
.0
01
 
0.
88
 
0.
11
 
…
 
0.
01
 
0.
00
4 
<0
.0
01
 
-0
.0
7 
-0
.4
0 
0.
99
 
 
1.
16
 
0.
23
 
…
 
0.
52
 
0.
54
 
-0
.4
9 
…
 
0.
98
 (0
.9
6-
1.
01
) 
0.
67
 (0
.4
1-
1.
11
) 
2.
70
 (1
.7
3-
4.
22
) 
 
3.
18
 (2
.0
9-
4.
83
) 
1.
25
 (0
.4
6-
3.
46
) 
…
 
1.
68
 (1
.0
3-
2.
76
) 
1.
73
 (0
.8
0-
3.
77
) 
0.
61
 (0
.4
1-
0.
96
) 
…
 
0.
1 
0.
12
 
<0
.0
01
 
 
<0
.0
01
 
0.
66
 
…
 
0.
04
 
0.
17
 
0.
02
 
…
 
*C
ha
ra
ct
er
is
tic
s 
th
at
 h
ad
 a
n 
in
de
pe
nd
en
t 
re
la
tio
ns
hi
p 
w
ith
 t
he
 d
ec
is
io
n 
to
 p
re
sc
rib
e 
st
at
in
s 
or
 ß
-b
lo
ck
er
s 
at
 p
=0
.2
5,
 a
nd
 w
er
e 
in
cl
ud
ed
 t
he
 
m
ul
tiv
ar
ia
bl
e 
lo
gi
st
ic
 r
eg
re
ss
io
n 
m
od
el
 t
o 
fo
rm
 t
he
 p
ro
pe
ns
ity
 s
co
re
; 
C
I, 
co
nf
id
en
ce
 in
te
rv
al
; 
E
lli
ps
es
 in
di
ca
te
 v
ar
ia
bl
es
 t
ha
t 
di
d 
no
t 
re
ac
h 
a 
p=
02
5 
le
ve
l t
o 
be
 in
cl
ud
ed
 in
 th
e 
m
ul
tiv
ar
ia
bl
e 
lo
gi
st
ic
 re
gr
es
si
on
 m
od
el
s 
  
 
166 
Multivariable analyses 
 Patients with advanced age (>70 years) and with a history of pulmonary 
disease remained at an elevated risk for perioperative mortality and nonfatal MI after 
an adjustment for the Revised Cardiac Risk Index (Table 4). One point increase in 
the Revised Cardiac Risk index was also significantly associated with adverse 
perioperative outcomes. Finally, the association between statins, beta-blockers and 
the composite endpoint remained statistically significant. Both, statin and beta-
blocker use were associated with 4-fold reduction in perioperative mortality and 
nonfatal myocardial infarction. In a separate model, a trend for aspirin and ACE-
inhibitors to reduce the likelihood for perioperative mortality and MI was revealed but 
these associations were not statistically significant. The combination of the Revised 
Cardiac Risk Index, statin and beta-blocker use with the corresponding propensity 
scores had excellent discriminatory power and good fit (c-index, 0.86; overall 
goodness-of-fit Hosmer-Lemeshow test; X2 =2.9, p=0.93). 
 
Table 4. Multivariable relation between clinical characteristics, statin and beta-
blocker use and perioperative mortality or myocardial infarction 
Variables Odds Ratios (95% 
Confidence Interval) 
X2 Test P-value 
Age > 70 years 
Chronic pulmonary disease 
Revised Cardiac Risk Index* 
One point increase 
Beta-blocker use 
Propensity score for beta-blocker use 
Statin use 
Propensity score for statin use 
 
 
 
 
 
 
 
 
3.0 (1.23-7.30) 
5.57 (2.60-12.0) 
 
3.52 (2.10-6.03) 
0.24 (0.11-0.54) 
3.51 (0.13-92.78) 
0.24 (0.10-0.70) 
5.17 (0.34-79.10) 
5.8 
19.3 
 
21.1 
11.7 
0.6 
6.8 
1.4 
0.02 
<0.001 
 
<0.001 
0.001 
0.5 
0.01 
0.2 
*To compose the Revised Cardiac Risk Index 1 point is assigned to each of the following 
characteristics: high-risk type of surgery, known ischemic heart disease (history of 
myocardial infarction, positive dobutamine stress echocardiography, history of angina 
pectoris), history of heart failure, history of cerebrovascular disease, diabetes mellitus, and 
preoperative serum creatinine level > 2.0 mg/dL. 
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Combined effect of statins and beta-blockers according to the Revised Cardiac 
Risk Index 
Based on the number of clinical risk scores, a combination of statin and beta-
blocker use the incidence of the composite endpoint was calculated (Figure 1). 
Patients with a risk score of 1 had a low event rate, with those receiving combine 
therapy tending to experience the lowest event rates (p=ns). Although not statistically 
significant, a similar relationship was observed in patients with a risk score of 2. 
However, in patients at highest risk (risk score of 3 or more) a significant descending 
gradation of risk was revealed with those on combined therapy experiencing only 
7.7% perioperative event rates. 
 
Figure 1. Incidence of perioperative mortality and myocardial infarction. 
 
Results are based on the number of clinical risk factors by the Revised Cardiac Risk Index 
(ischemic heart disease, history of congestive heart failure, history of cerebrovascular 
disease, insulin therapy for diabetes, preoperative serum creatinine > 2mg/dL), statin and 
beta-blocker use. 
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Discussion 
 The current study showed that clinical risk factors and DSE data aggregated in 
the Revised Cardiac Risk index were significant predictors of perioperative mortality 
and nonfatal MI. In addition patients who were statin users had a four-fold reduced 
risk of perioperative events. Although, statin users had a different clinical risk profile 
than nonusers, this association remained after adjustment for these differences. 
Furthermore, our findings also suggest the benefit of combined therapy with statins 
and beta-blockers especially in patients at the highest risk as defined by the Revised 
Cardiac Risk Index. 
Clinical predictors of adverse perioperative outcome for patients with 
abdominal aortic surgery have been well documented and clearly identify a history of 
CAD, renal dysfunction and pulmonary comorbidity as having prognostic significance 
in these patients (23, 24, 26). Still, cardiac complications such as cardiac death and 
nonfatal MI are the most frequently observed perioperative adverse events in these 
patients. Among patients in whom postmortem examination was performed in the 
present study, the cause of death was more often classified as cardiac than in 
patients who died but did not undergo autopsy (50% vs. 21%). This suggests that the 
incidence and impact of cardiac complications after abdominal aortic surgery could 
be underestimated in clinical practice. There is growing evidence, which points to an 
association between the presence of an abdominal aortic aneurysm, and 
atherosclerosis (27, 28), which may well explain the observed high proportion of 
adverse events due to cardiovascular causes. While favorable actions of statins on 
atherosclerosis and vascular properties have mainly been attributed to cholesterol 
lowering (19-21, 29-32), statins may also attenuate coronary artery plaque 
inflammation, influence plaque stability in addition to antithrombogenic, 
antiproliferative and leukocyte-adhesion inhibiting effects (19-21, 33). All these 
properties of statins may stabilize unstable coronary plaques, and thereby reducing 
myocardial ischemia and subsequent myocardial damage. 
 Consistent with previous studies, an association between beta-blocker use 
and reduced perioperative events was observed (10, 11). Despite that beta-blocker 
users were more often statin users, there was no evidence of differential beneficial 
effect of statin use on beta-blocker therapy. Thus, statin use appears to be 
independently associated with a reduced incidence of perioperative mortality and MI 
even in the presence of beta-blockers. Beta-blockers apart form their direct 
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hemodynamic effect such as reduction in heart rate and contractility may also 
indirectly influence the determinants of shear stress and reduce inflammation through 
decreases in sympathetic tone (34). These properties of beta-blockers may reinforce 
the effect of statins on vulnerable plaques. 
 To date, there are few studies that have evaluated the effect of statin use on 
the reduction of perioperative and short-term cardiovascular complications in patients 
undergoing vascular surgery (35, 36). In a preliminary study by Durazzo et al., a 
marked reduction of adverse cardiovascular events among vascular surgery patients 
who were randomly assigned to atorvastatin compared with placebo was reported 
(35). The study showed that short-term (within six months) treatment with 
atorvastatin significantly reduced the incidence of cardiovascular events after 
vascular surgery (atorvastatin vs. placebo, 8.3% vs. 26.0%). Landesberg et al (36) 
also found that patients who underwent major vascular surgery and were using lipid-
lowering therapy had a tendency for better event-free survival rates. In our previous 
case-control study, we found that statin users had a nearly five-fold reduction of in-
hospital mortality as compared to nonusers (22). The current study builds upon these 
earlier findings by highlighting the combined beneficial effect of statin and beta-
blocker use for the reduction not only of perioperative mortality but also nonfatal MI in 
a large cohort of patients undergoing elective AAA-surgery. Secondly, the Revised 
Cardiac Risk Index was also applied to adjust for important clinical risk factors. 
Finally, we used propensity scores and multivariable modeling to adjust for potential 
confounders. Beta-blockers may offer protection in patients at low- to intermediate 
risk but their effect appears to be marginal in patients at the highest risk (12). In this 
context, statins appear to have additional beneficial effect for the prevention of 
perioperative mortality and nonfatal MI. 
 This study has certain limitations, which should be considered when 
interpreting the results. Statin users had more often a history of CAD and renal 
dysfunction, and as a result of that, were more often prescribed other cardiac 
medications or underwent previous coronary revascularization prior to the elective 
AAA-surgery. It is possible, therefore that statin users would have also been more 
likely to receive better medical attention during the perioperative period. Moreover, 
the incidence of perioperative mortality was relatively higher than reported from other 
studies (2.7% to 5.5%) (23). This may question the generalizability of our findings. 
However, it is important to note that patients in this study were operated in a tertiary 
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referral center, and studies that reported lower mortality rates usually implied strict 
inclusion criteria and selected patients at low risk for perioperative complications 
(23). Finally, given the retrospective nature of our study it was not possible to 
ascertain unless it was clearly stated in the medical records whether treatment with 
statins was discontinued throughout the perioperative period or discontinued during 
hospitalization. This could be particularly relevant since current American Heart 
Association Clinical Advisory Statement on statin safety suggests the discontinuation 
of statin treatment during major surgery or critical illness (37). Conversely a recent 
study has suggested that discontinuation of statins may be associated with adverse 
outcomes in hospitalized patients (38). 
 
Conclusions 
This study revealed that a combination of statin and beta-blocker use in 
patients undergoing AAA-surgery is associated not only with a reduced incidence of 
perioperative mortality but also nonfatal MI, particularly in patients at the highest risk 
for perioperative complications. This early evidence of the beneficial effect of statin 
use particularly in combination with beta-blocker use should be confirmed in future 
large-scale clinical trials. 
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Optimizing long-term cardiac management after major 
vascular surgery. Role of beta-blocker therapy, clinical 
characteristics, and dobutamine stress echocardiography 
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after successful abdominal aortic aneurysm surgery 
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Summary and conclusions 
 
 
In this thesis, the prognostic value of clinical risk factors, the use of 
noninvasive testing for risk stratification, and pharmacologic risk reduction strategies 
are described for the perioperative and long-term management of patients 
undergoing major vascular surgery. 
 
Part 1: Preoperative risk evaluation-clinical risk factors 
 
In chapter 1, a systematic review is given summarizing the issue of 
perioperative risk evaluation and management of patients undergoing major vascular 
surgery. This chapter describes the burden of peripheral artery disease, 
pathophysiology of perioperative cardiac events, risk assessment and risk reduction 
strategies. The summarized data from published literature show that patients without 
cardiac risk factors are considered to be at low risk and no additional evaluation for 
coronary artery disease is recommended; beta-blockers may reduce perioperative 
cardiac events in this patient population; patients with one or more cardiac risk 
factors represent an intermediate to high-risk population. Additional noninvasive 
testing for the evaluation of coronary artery disease is recommended. Beta-blockers 
should be prescribed to all patients and coronary artery revascularization should be 
reserved for patients who have a clearly defined need for revascularization, 
independent of the need for surgery. 
 
In chapter 2, a comparison is made between serum creatinine and creatinine 
clearance for the prediction of postoperative mortality in patients undergoing major 
vascular surgery. The results show that preoperative creatinine clearance derived 
from serum creatinine, age, body weight and gender had additional prognostic value 
compared to serum creatinine to predict postoperative mortality in patients 
undergoing major vascular surgery. Measures that may improve or preserve the 
renal function during and after surgery may help to reduce postoperative mortality in 
this high-risk patient population. 
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In chapter 3, we describe a relation between the presence of aortic stenosis 
and an increased risk of perioperative mortality. Aortic stenosis is the most common 
valvular heart disease affecting 2% to 9% of adults over 65 years of age. Earlier 
studies showed that patients with aortic stenosis were at increased risk of life-
threatening or fatal cardiac complications. Later, three studies reported that selected 
patients with aortic stenosis who were not candidates for, or refused, aortic valve 
replacement could undergo noncardiac surgery with a reasonably low event rate. 
However, a more recent study reported that peak instantaneous gradients were 
associated with increased cardiovascular mortality. Therefore, in this chapter we 
compared the incidence of perioperative mortality and nonfatal myocardial infarction 
in a large group of patients with moderate to severe aortic stenosis who were 
undergoing elective noncardiac surgery to patients without aortic stenosis. We found 
that patients with aortic stenosis were at five-fold increased risk for cardiac 
complications compared to patients without aortic stenosis. 
 
In chapter 4, the safety of dobutamine stress echocardiography in patients 
with aortic stenosis is described. Low-dose dobutamine stress echocardiography is a 
recommended investigation in patients with low-gradient aortic stenosis and reduced 
left ventricular function to assess whether the aortic stenosis is fixed or dynamic. 
Patients with aortic stenosis and normal or mildly reduced left ventricular function 
may be referred for dobutamine stress echocardiography for the diagnosis of 
coronary artery disease, or for risk stratification before noncardiac surgery. However, 
only few data are available relating to the safety of dobutamine stress 
echocardiography in these patients. Therefore, in this chapter the safety of 
dobutamine stress echocardiography was studied in 75 patients with aortic stenosis 
and with severely reduced or moderate to normal left ventricular function. The mean 
pressure gradient, valve area and side effects after dobutamine stress 
echocardiography were evaluated. Serious cardiac arrhythmias occurred in 10 
patients. Among 20 patients with evidence of ischemia on dobutamine stress 
echocardiography, three developed adverse side effects. The results showed that 
patients with a low-gradient aortic stenosis and left ventricular dysfunction were 
susceptible to potentially life-threatening arrhythmias during dobutamine stress 
echocardiography. In these patients an alternative noninvasive test for the diagnosis 
of coronary artery disease, such as myocardial perfusion scintigraphy should be 
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considered. In patients with mild to moderate aortic stenosis, and with normal or 
mildly reduced left ventricular function, dobutamine stress echocardiography was 
relatively safe, but arrhythmias and hypotension were noted during a high-dose 
dobutamine challenge. 
 
In chapter 5, the long-term prognostic value of asymptomatic cardiac troponin 
T elevations in patients after successful major vascular surgery is studied. A follow-
up study was conducted between 1996 and 2000 in 393 patients who underwent 
successful aortic or infrainguinal vascular surgery and routine sampling of cardiac 
troponin T. Patients were followed for on average period of four years and the 
incidence of all-cause mortality was evaluated. The presence of cardiac troponin T 
elevations was associated with an almost two-fold increased risk of long-term 
mortality in patients undergoing successful major vascular surgery, independent of 
the presence of risk factors for coronary artery disease, renal dysfunction, cardiac 
medication use, and elevated CK levels. Additional clinical studies are required to 
determine the most optimal approach and management for patients with abnormal 
cardiac troponin T levels to improve their long-term outcome. 
 
In chapter 6, the relation between clinical risk factors and perioperative 
mortality is studied in patients who underwent elective abdominal aortic aneurysm 
surgery. Patients undergoing elective open abdominal aortic surgery are at increased 
risk for perioperative mortality. Identification of preoperative factors associated with 
increased risk of mortality may initiate preoperative interventions and influence 
decisions about the type and also the timing of the surgery. A number a risk factors 
of perioperative mortality in elective abdominal aortic aneurysm surgery have been 
identified. These risk factors have been incorporated in clinical risk models such as 
the Leiden and the United Kingdom Small Aneurysm Trial risk scores. However, the 
performance of these risk models were not evaluated in other more recent datasets. 
In this chapter we studied the performance of the Leiden and the United Kingdom 
Small Aneurysm Trial risk scores. Our results show that the Leiden risk model could 
identify a low-risk population of patients. The United Kingdom Small Aneurysm Trial 
risk model had only relatively poor performance and, hence, was not a suitable 
alternative to the Leiden risk model. 
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In chapter 7, we use data of 75,581 patients who underwent 108,613 
noncardiac surgical procedures between 1991-2000 at the Erasmus MC to examine 
trends in the incidence of fatal perioperative cardiovascular complications over time, 
and study the relationship between clinical and electrocardiographic variables and 
fatal cardiovascular outcome. There were no significant changes in cardiovascular 
mortality over time in either men or in women. Advanced age, male gender, type of 
surgery, diabetes mellitus, hypertension, ischemic heart disease, heart failure, stroke, 
and renal failure were identified as important clinical risk factors for cardiovascular 
death. An abnormal ECG was also associated with increased perioperative 
cardiovascular mortality. Based on these results, a score was developed to estimate 
an individual patient’s risk of cardiovascular death in relation to a specific surgical 
procedure. The results showed that the developed multivariable risk models showed 
excellent ability to discriminate between patients at low, intermediate and high risk of 
cardiovascular complications, and can readily be applied in routine perioperative 
management. 
 
Part 2: Preoperative cardiac risk evaluation-noninvasive testing 
 
In chapter 8, in a scientific letter we propose that the decision about to perform 
early surgery for abdominal aortic aneurysm or institute ultrasonographic surveillance 
should be made on an individual basis, after an evaluation of the perioperative risk. 
Based on data of 661 patients operated for abdominal aortic aneurysm surgery 
between 1991 and 2000 at the Erasmus MC, patients without chronic pulmonary 
disease or cardiac risk factors represent a population at low risk for operative death. 
Patients with one or more cardiac risk factors could be further stratified by the 
absence or presence and extent of myocardial ischemia, as determined by 
dobutamine stress echocardiography. In this way risk assessment and modification 
could be undertaken for each patient. 
 
In chapter 9, the additional prognostic value of dobutamine stress 
echocardiography, dipyridamole stress echocardiography and dipyridamole perfusion 
scintigraphy are compared in patients undergoing major vascular surgery. We used 
data of 2,204 consecutive patients who underwent either of these noninvasive tests 
before major vascular surgery. We found no statistically significant difference in the 
  
 
197
predictive value of a positive test result for dobutamine stress echocardiography and 
dipyridamole stress echocardiography (Odds ratio of 37.1 [95% CI, 8.1-170.1] versus 
9.6 [95% CI, 4.9-18.4]; p=0.12), whereas a positive test for dipyridamole perfusion 
scintigraphy had significantly lower prognostic value (Odds ratio of 1.95 [95% CI, 1.2-
3.2]). In further analyses the additional prognostic value of these tests modalities 
were studied on clinical risk factors. Our results show that dobutamine or 
dipyridamole stress echocardiography had more favorable prognostic performance, 
irrespective of clinical risk profile. In contrast, the prognostic value of dipyridamole 
perfusion scintigraphy is more likely to be dependent on patients’ clinical risk score. 
 
In chapter 10, a meta-analysis comparing the prognostic accuracy of six 
diagnostic tests for predicting perioperative cardiac risk in patients undergoing major 
vascular surgery is described. The identification of clinical risk factors and the role of 
noninvasive diagnostic testing to predict perioperative cardiac risk have been 
evaluated over recent decades. These have included multifactorial clinical scoring 
systems based upon, noninvasive tests such as ambulatory electrocardiography, 
exercise electrocardiography, radionuclide ventriculography, myocardial perfusion 
scintigraphy, and dipyridamole or dobutamine stress echocardiography. Using a 
novel meta-analytic method we systematically summarized data for the available 
literature. In all, 58 studies with a total of 8,119 patients met the inclusion criteria. 
Dobutamine stress echocardiography showed a positive trend towards better 
diagnostic performance than the other tests, but reached only statistical difference in 
comparison with myocardial perfusion scintigraphy. However, dobutamine stress 
echocardiography could be the favoured test if there is a suspicion about valvular 
and left ventricular dysfunction. 
 
Part 3: Perioperative pharmacological therapy 
 
In chapter 11, in an editorial review the possible reasons to withhold beta-
blockers from high-risk patients with coronary artery disease are described. In this 
editorial, we analyzed issues such as how often beta-blockers are underused, the 
possible reasons for withholding beta-blockers and recommendations. 
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Next in chapter 12, the first study is described that revealed an association 
between statin use and a reduced incidence of perioperative mortality in patients 
undergoing major noncardiac vascular surgery. Patients undergoing major vascular 
surgery are at increased risk of perioperative mortality due to underlying coronary 
artery disease. Statins may reduce perioperative mortality through the improvement 
of lipid profile, but also through the stabilization of coronary plaques on the vascular 
wall. To evaluate this association a case-control study was performed among the 
2,816 patients who underwent major vascular surgery from 1991 to 2000 at the 
Erasmus MC. Case subjects were all 160 (5.8%) patients who died during the 
hospital stay after surgery. From the remaining patients, two controls were selected 
for each case and were stratified according to calendar year and type of surgery. The 
data showed that statin therapy was significantly less common in cases than in 
controls (8% versus 25%; P<0.001). The adjusted odds ratio for perioperative 
mortality among statin users as compared with nonusers was 0.22 (95% CI, 0.10-
0.47). This study provided evidence for the first time that statin use reduces 
perioperative mortality in patients undergoing major vascular surgery. 
 
In chapter 13, the combined effect of perioperative statin and beta-blocker use 
in relation to perioperative mortality is described. Five hundred seventy patients who 
underwent elective abdominal aortic aneurysm surgery were studied between 1991-
2000 at the Erasmus Medical Center. Patients were evaluated for clinical risk factors, 
statin and beta-blocker use. The main outcome measure was a composite of all 
cause mortality and nonfatal myocardial infarction within 30 days of surgery. The 
findings of this study revealed that the incidence of the composite endpoint was 
significantly lower in statin users compared to non-statin users (3.7% vs. 11.0%; 
adjusted odds ratio: 0.24, 95% CI, 0.10-0.70; p=0.01). Beta-blocker use was also 
associated with a significant reduction in the composite endpoint (adjusted odds: 
0.24, 95% CI, 0.11-0.54). Despite the fact that beta-blocker users were more often 
statin users there was no evidence of differential beneficial effect of statin use on 
beta-blocker therapy. Thus, statin use appears to be independently associated with a 
reduced incidence of perioperative mortality and nonfatal myocardial infarction even 
in the presence of beta-blockers. 
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Part 4: Long-term pharmacological therapy 
 
In chapter 14, the optimal long-term cardiac management after major vascular 
surgery is described. This study was performed based on the long-term follow-up 
data of the Dutch Echocardiographic Cardiac Risk Evaluation Applying Stress 
Echocardiography study. The follow-up study was conducted in 1,286 patients of the 
1,351 patients who survived surgery for at least 30 days. The results of the present 
study shows that stress-induced ischemia during dobutamine stress 
echocardiography has additional prognostic value, irrespective of the clinical risk 
profile. Patients receiving beta-blockers had significantly lower risk than patients not 
receiving them. However, the cardioprotective effect of beta-blockers was more likely 
to depend on the presence or absence of cardiac risk factors and stress-induced 
myocardial ischemia during dobutamine stress echocardiography testing. 
 
In chapter 15, we studied the association between long-term statin use and 
mortality after successful abdominal aortic aneurysm surgery. The main finding of 
this study is that the incidence of all-cause and cardiovascular mortality was 
significantly lower in statin users than in nonstatin users. After adjusting for clinical 
risk factors and beta-blocker use, the association between statin use and reduced all-
cause (hazard ratio: 0.4, 95% CI, 0.3-0.6) and cardiovascular (hazard ratio: 0.3, 95% 
CI, 0.2-0.6) mortality persisted. It seems, therefore, that long-term statin use should 
be considered in patients following abdominal aortic aneurysm surgery. 
 
In conclusion, perioperative and long-term cardiac risk assessment and 
management of patients undergoing major vascular surgery is one of the most 
challenging and controversial areas of clinical medicine. With the help of our 
research we showed that by applying appropriate preoperative risk stratification tools 
and perioperative and long-term risk reduction strategies these patients may safely 
undergo surgery and survive the perioperative period in order to benefit from their 
surgery in the short and long-term. 
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Samenvatting en conclusies 
 
 
In dit proefschrift worden de prognostische waarde van klinische 
risicofactoren, het gebruik van niet-invasieve onderzoekstechnieken voor 
risicostratificatie, farmacologische risicoreductie strategieën beschreven voor  peri-
operatieve en lange termijn beleid bij patiënten die een grote vaatoperatie hebben 
ondergaan. 
 
Part 1: Pre-operatieve risico-evaluatie – klinische risicofactoren 
 
In hoofdstuk 1 wordt de peri-operatieve risico-evaluatie en de behandeling van 
patiënten, die een grote vaatoperatie ondergaan, samengevat. Dit hoofdstuk 
beschrijft de last van perifeer vaatlijden, de pathosfysiologie van peri-operatieve 
cardiale events, risicoschatting en strategieën voor risicoreductie. De resultaten van 
huidige publicaties laten zien dat patiënten zonder cardiale risicofactoren beschouwd 
worden als een laagrisico groep en voor deze groep wordt geen aanvullende 
evaluatie van het coronairlijden aanbevolen. Verder zouden beta-blokkers in deze 
groep patiënten het risico op peri-operatieve cardiale events kunnen verlagen. 
Daarentegen, patiënten met een of meerdere cardiale risicofactoren worden 
beschouwd als een groep met een gemiddeld tot hoog risico. Aanvullende non-
invasieve testen voor de evaluatie van het coronairlijden wordt in deze groep wel 
aanbevolen. Bèta-blokkers zouden moeten worden voorgeschreven aan alle 
patiënten en coronaire revascularisatie zou moeten worden geïndiceerd voor 
patiënten waarvoor een duidelijke noodzaak voor revascularisatie bestaat, 
onafhankelijk van de noodzaak tot operatie. 
 
In hoofdstuk 2 wordt een vergelijking gemaakt tussen serum creatinine en de 
creatinine-klaring voor het voorspellen van peri-operatieve sterfte in patiënten die 
een grote vaatoperatie ondergaan. De resultaten laten zien dat de peri-operatieve 
creatinine-klaring afkomstig van het serum-creatinine, leeftijd, lichaamsgewicht en 
geslacht een aanvullende prognostische waarde hebben in vergelijking tot het 
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serum-creatinine om de peri-operatieve sterfte te voorspellen in patiënten die een 
grote vaatoperatie ondergaan. Maatregelen die de nierfunctie mogelijk zouden 
kunnen behouden tijdens en na de operatie zouden de peri-operatieve sterfte in 
hoogrisico patiënten kunnen verlagen.  
 
In hoofdstuk 3 wordt de relatie beschreven tussen de aanwezigheid van een 
aorta-stenose en het verhoogde risico op peri-operatieve sterfte. Aorta-stenose is de 
meest voorkomende klepaandoening en treft 2% tot 9% van de volwassen boven de 
65 jaar. Eerdere studies hebben aangetoond dat patiënten met een aorta-stenose 
een verhoogd risico hebben op levensbedreigende of zelfs fatale cardiale 
complicaties. Drie latere studies hebben aangetoond dat bepaalde patiënten met 
aorta-stenose die niet in aanmerking kwamen voor aorta-klep vervanging of die dit 
weigerde, non-cardiale operaties kunnen ondergaan met een redelijk laag aantal 
events. Een meer recente studie heeft echter laten zien dat peak aorta-stenose 
gradiënt geassocieerd zijn met een toename van de cardiovasculaire sterfte. Daarom 
wordt in dit hoofdstuk de incidentie van peri-operatieve sterfte en non-fataal 
myocardinfarct vergeleken in een grote groep patiënten met een matig tot ernstige 
aorta-stenose in patiënten zonder aorta-stenose die een electieve non-cardiale 
operatie ondergaan. De resultaten van onze studie laten zien dat patiënten met een 
aorta-stenose een 5 keer hoger risico hebben op cardiale complicaties in vergelijking 
tot patiënten zonder aorta-stenose. 
 
In hoofdstuk 4 wordt de veiligheid van dobutamine stress echocardiografie 
beschreven in patiënten met een aorta-stenose. Lage-dosering dobutamine stress 
echocardiografie wordt aanbevolen in patiënten met een lage-gradient aorta-stenose 
en een verminderde linker-ventrikel functie om te bepalen of de aorta-stenose 
gefixeerd is of dynamisch. Patiënten met een aorta-stenose en een normale of licht 
verminderde linker-ventrikel functie kunnen worden doorverwezen voor een 
dobutamine stress echocardiografie voor de diagnose van coronairlijden of voor 
risicostratificatie voor een non-cardiale operatie. Er zijn echter maar weinig gegevens 
beschikbaar met betrekking tot de veiligheid van dobutamine stress echocardiografie 
in deze groep patiënten. In dit hoofdstuk wordt daarom de veiligheid van dobutamine 
stress echocardiografie bestudeerd in 75 patiënten met een aorta-stenose en een 
ernstige verminderde of matig tot normale linker-ventrikel functie. Er is gekeken naar 
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de gemiddelde druk-gradient, klepoppervlak en de bijwerkingen na de dobutamine 
stress echocardiografie. In 10 patienten was er sprake van ernstige arhytmieen en 
van de 20 patiënten met bewezen ischemie op de dobutamine stress 
echocardiografie ontwikkelde 3 patienten ongunstige bijwerkingen. De data laten zien 
dat patiënten met een lage-gradient aorta-stenose en een linker-ventrikel dysfunctie 
gevoelig waren voor eventuele levensbedreigende arytmieën. In deze groep 
patienten zou een alternatieve non-invasieve test moeten worden overwogen voor de 
diagnose coronairlijden, zoals bijvoorbeeld myocardial perfusie scintigrafie. In 
patiënten met een milde tot matige aorta-stenose en met een normale of slechts 
lichte vermindering van de linker-ventrikel-functie was de dobutamine stress 
echocardiografie relatief veilig, maar was er tijdens een hoge-dosering dobutamine 
stress echocardiografie wel sprake van arhytmieën en hypotensie.  
 
In hoofdstuk 5 is de lange-termijn prognostische waarde van asymptomatisch 
cardiale troponine T verhogingen na een geslaagde grote vaatoperatie bestudeerd. 
In de periode tussen 1996 en 2000 is er een lange-termijn follow-up studie 
uitgevoerd in 393 patiënten die een geslaagde operatie van de aorta of infrainguinale 
vaatoperatie hadden gehad en waarbij routinematig cardiaal troponine T was 
bepaald. Deze patiënten werden gemiddeld 4 jaar gevolgd en er is gekeken naar de 
incidentie van totale sterfte. Een verhoging van troponine T was geassocieerd met 
een bijna 2 keer zo hoog risico op sterfte op de lange-termijn in patienten die een 
geslaagde grote vaatoperatie hadden gehad, onafhankelijk van de aanwezigheid van 
risicofactoren voor coronairlijden, dysfunctioneren van de nieren, cardiale 
medicatiegebruik en verhoogde CK-waarden. Aanvullende klinische studies zijn 
nodig om de meest optimale benadering en behandeling te bepalen voor patiënten 
met abnormale troponine T waarden om hun uitkomst op lange-termijn te verbeteren. 
 
In hoofdstuk 6 wordt de relatie tussen klinische risicofactoren en peri-
operatieve sterfte bestudeerd in patiënten die een electieve abdominale aorta 
aneurysma operatie ondergaan. Patiënten die een electieve abdominale aorta 
aneurysma operatie ondergaan hebben een verhoogd risico op peri-operatieve 
strefte. Identificatie van de pre-operatieve factoren die geassocieerd zijn met een 
verhoogd risico op sterfte kunnen aanleiding geven tot pre-operatieve interventies en 
beslissingen beïnvloeden met betrekking tot type en tijdstip van de operatie. Er zijn 
  
 
204 
een aantal klinische risicofactoren geïdentificeerd voor de peri-operatieve sterfte in 
electieve abdominale aneurysma operaties.  Deze factoren zijn ingebouwd in 
klinische risicomodellen zoals de Leiden en United Kingdom Small Aneurysm Trial  
risicoscores. De uitvoering van deze risicomodellen zijn echter nog niet geëvalueerd 
in andere, meer recente databases. In dit hoofdstuk hebben we de uitvoering van de 
Leiden en United Kingdom Small Aneurysm Trial risico-scores bestudeerd. De 
resultaten laten zien dat Leiden risicomodel een laagrisico patienten-populatie zou 
kunnen identificeren. Het United Kingdom Small Aneurysm Trial risicomodel geeft 
een  relatief slecht resultaat en is dus geen geschikt alternatief voor het Leiden 
risicomodel.  
 
In hoofdstuk 7 hebben we de data van 75.581 patiënten onderzocht die in 
totaal 108.613 non-cardiale operaties hebben ondergaan in de periode van 1991 en 
2000 in het Erasmus Medisch Centrum om het beloop van de incidentie van fatale 
peri-operatieve cardiovasculaire complicaties te bestuderen. Bovendien is de relatie 
tussen zowel klinische en electrocardiografische variabelen en fatale 
cardiovasculaire uitkomsten bestudeerd. Er zijn geen significante veranderingen in 
cardiovasculaire sterfte in de tijd waargenomen in mannen en vrouwen. Oudere 
leeftijd, mannelijk geslacht, type operatie, diabetes mellitus, hypertensie, 
ischemische hartziekte, hartfalen, beroerte en nierfalen zijn geïdentificeerd als 
belangrijke klinische risicofactoren voor cardiovasculaire sterfte. Een abnormaal ECG 
was ook geassocieerd met een stijging van de cardiovasculaire sterfte. Gebaseerd 
op deze resulaten is er een score ontwikkeld om het individuele risico te schatten van 
een patiënt op cardiovasculaire sterfte in relatie tot een specifieke operatie. De 
resultaten laten zien dat deze multivariabele risico-modellen goed in staat zijn om 
onderscheid te maken tussen patiënten die een laag, gemiddeld en hoog risico op 
cardiovasculaire complicaties en kunnen nu routinematig worden toegepast in peri-
operatieve behandeling. 
 
Deel 2: Pre-operatieve cardiale risico evaluatie – niet invasieve onderzoeken 
 
In hoofdstuk 8, wordt aan de hand van een wetenschappelijke brief 
voorgesteld om op basis van individuele besluitvorming, na evaluatie van het peri-
operatieve risico, te kiezen voor vroegtijdige operatie van een abdominalis aorta 
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aneurisma of een regelmatige echocardiografische controle. Dit voorstel is 
gebaseerd op de gegevens van 661 patiënten die tussen 1991 en 2000 in het 
Erasmus MC een operatie ondergingen van een aneurisma aorta abdominalis. Een 
laag risico op operatieve mortaliteit wordt ingeschat als patiënten geen chronische 
longaandoening of cardiale risicofactoren heeft. Indien er sprake is van één of meer 
cardiale risicofactoren wordt verder uitgesplitst op het wel of niet aanwezig zijn van 
cardiale ischemie en de uitgebreidheid hiervan. Dit wordt bepaald aan de hand van 
dobutamine stressechocardiografie. Deze wijze van inschatting kon voor iedere 
patiënt worden uitgevoerd.   
 
In hoofdstuk 9 wordt de toegevoegde prognostische waarde van dobutamine 
stress echocardiografie, dipyridamol stress echocardiografie en perfusie scintigrafie 
vergeleken bij patiënten die een grote vaatoperatie ondergingen. Hiervoor werden de 
gegevens van 2204 opeenvolgende patiënten gebruikt bij wie één van deze niet-
invasieve onderzoeken werd verricht voorafgaand aan een grote vaatoperatie. Er 
werden geen statistisch significante verschillen gevonden tussen de prognostische 
waarde van een positieve test van de dobutamine stress echocardiografie en 
dipyridamol stress echocardiografie (Odds ratio: 37.1 [95% CI, 8.1-170.1] versus 9.6 
[95% CI, 4.9-18.4]; p=0.12), terwijl een positieve dipyridamole perfusie scintigrafie 
een significant lagere prognostische waarde had (Odds ratio: 1.95 [95% CI, 1.2-3.2]. 
Aanvullende analyses werden verricht naar de toegevoegde prognostische waarde 
van deze onderzoeksmethoden met betrekking tot klinische risicofactoren. Onze 
resultaten laten zien dat dobutamine of dipyramidamol stress echocardiografie een 
gunstiger prognostisch beeld liet zien, ongeacht het klinisch risico profiel. Dit in 
tegenstelling tot de voorspellende waarde van dipyridamol perfusie scintigrafie, 
waarbij het klinische risico profiel wel van invloed leek te zijn. 
 
In hoofdstuk 10 wordt een meta-analyse beschreven, waarin zes verschillende 
diagnostische onderzoeken met elkaar worden vergeleken op prognostische 
accuraatheid om het peri-operatieve cardiale risico te voorspellen bij patiënten die 
een grote vaatoperatie ondergaan. Ook worden klinische risico factoren 
geïdentificeerd en de rol van niet-invasieve diagnostische onderzoeken bij het 
voorspellen van het peri-operatieve cardiale risico. Dit omvatte multifactoriële 
klinische scoringssystemen die gebaseerd waren op, niet-invasieve onderzoeken 
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zoals electrocardiografie, inspannings electrocardiografie, radionuclide 
ventriculografie, myocard perfusie scitigrafie en dobutamine of dipyramidamole 
stress echocardiografie.  Met behulp van een nieuwe meta-analyse methode werd op 
een systematische wijze de gegevens van de beschikbare literatuur samengevat. 
Uiteindelijk voldeden 58 onderzoeken met in totaal 8,119 patiënten aan de 
inclusiecriteria. Dobutamine stress echocardiografie liet een positieve trend zien met 
betrekking tot een betere diagnostiek in vergelijking met andere onderzoeken, maar 
verschilde alleen statistisch significant met myocard perfusie scintigrafie. Hoewel, de 
voorkeur uitgaat naar dobutamine stress echocardiografie is er enige twijfel over de 
betrouwbaarheid bij patiënten met een hartklepaandoening en linker-ventrikel 
disfunctie. 
 
Deel 3: Peri-operatieve farmacolgische therapie 
 
In hoofdstuk 11 wordt in een editorial, een overzicht van de mogelijke redenen 
beschreven waarom in hoog-risisco patienten met coronairlijden geen bèta-blokkers 
wordt gegeven. In deze editorial worden verschillende kwesties geanalyseerd, zoals 
hoe vaak er sprake is van ondergebruik van bèta-blokkers, de mogelijke redenen 
voor het niet geven van bèta-blokkers en aanbevelingen.  
 
Vervolgens wordt in hoofdstuk 12 als eerste, een studie beschreven waarin 
een verband is aangetoond tussen het gebruik van cholesterolverlagens als statinen 
en een lagere peri-operatieve sterfte in patiënten die een grote niet-cardiale 
vaatoperatie ondergaan. Patiënten die een grote niet-cardiale vaatoperatie 
ondergaan, hebben een verhoogd risico op peri-operatieve sterfte als gevolg van 
onderliggend coronairlijden. Statinen kunnen de peri-operatieve sterfte enerzijds 
reduceren door een verbetering van het lipiden profiel en anderzijds door de 
stabilisatie van de coronaire plaques op de vaatwand. Om deze associatie te 
evalueren is er een case-control studie uitgevoerd in 2816 patiënten die een grote 
vaatoperatie hebben ondergaan in het Erasmus MC tussen 1991 en 2000. Voor deze 
studie zijn alle patiënten bekeken die tijdens of na de operatie overleden zijn in het 
ziekenhuis (160 patienten, 5.8%). De resultaten laten zien dat deze overleden 
patiënten significant minder vaak statinen kregen dan de controle patienten (18% 
versus 25%; P<0.001). De gecorrigeerde odds ratio voor peri-operatieve mortaliteit 
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bij patiënten die statinen krijgen in vergelijking tot diegenen die geen statinen krijgen 
was 0.22 (95% CI 0.10 – 0.47). Deze studie heeft voor het eerst aangetoond dat het 
gebruik van statinen de peri-operatieve sterfte reduceert in patiënten die een grote 
vaatoperatie ondergaan. 
 
In hoofdstuk 13 wordt het gecombineerde effect beschreven van het gebruik 
van statinen en bèta-blokkers in relatie tot de peri-operatieve sterfte. Er werden 570 
patienten bestudeerd die een electieve operatie van de abdominalis aorta aneurysma 
operatie hebben gehad in het Erasmus MC in de periode tussen 1991 en 2000. In 
deze patiënten werd gekeken naar klinische risicofactoren en het gebruik van 
statinen en bèta-blokkers. De belangrijkste uitkomstmaat was een combinatie van 
totale sterfte en non-fatale hartinfarct binnen 30 dagen na de operatie. De resultaten 
van deze studie tonen aan dat de incidentie van het bovengenoemde gecombineerde 
eindpunt significant lager was in diegenen die statinen gebruikten in vergelijking tot 
diegenen die geen statinen gebruikten (3.7% versus 11.0%; gecorrigeerde odds ratio 
0.24, 95% CI 0.10 – 0.70; P=0.01). Het gebruik van bèta-blokkers was ook 
geassocieerd met een significante reductie in het gecombineerde eindpunt 
(gecorrigeerde odds-ratio 0.24, 95% CI 0.11 – 0.54). Ondanks het feit dat degenen 
die bèta-blokkers gebruikten ook statinen gebruikten, is er geen bewijs geleverd dat 
er een differentieel gunstig effect bestaat van het gebruik van statinen op het gebruik 
van bèta-blokkers. Dus, het gebruik van statinen lijkt onafhankelijk geassocieerd te 
zijn met een lagere incidentie van peri-operative sterfte en non-fataal hartinfarct, zelfs 
wanneer er bèta-blokkers worden gebruikt. 
 
Deel 4: Langdurige farmacologische therapie 
 
In hoofdstuk 14 wordt ingegaan op de optimale lange termijn behandeling na 
een grote vaatoperatie. Centraal hierin staan de lange termijn follow-up gegevens 
van de Dutch Echocardiographic Cardiac Risk Evaluation Applying Stress 
Echocardiography studie. Dit onderzoek werd verricht onder 1286 van de 1351 
patiënten die 30 dagen na hun operatie nog in leven waren. De resultaten van dit 
onderzoek laten zien dat inspanningsgeïndiceerde ischemie tijdens een dobutamine 
stress echocardiogram van aanvullende prognostische waarde is, ongeacht het 
klinische risico profiel. Patiënten die een bèta-blokkers kregen bleken een significant 
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lager risico te hebben dan patiënten die geen bèta-blokker kregen. Hierbij dient wel 
te worden opgemerkt dat het gunstige effect van bèta-blokkers waarschijnlijk 
afhankelijk was van het al dan niet hebben van cardiale risicofactoren en 
inspanningsgeïndiceerde cardiale ischemie tijdens een dobutamine stress 
echocardiogram. 
 
 In hoofdstuk 15 wordt de associatie tussen het langdurig gebruik van statines 
en sterfte na een succesvolle operatie van een aorta aneurisma beschreven. De 
belangrijkste resultaten van dit onderzoek betreffen de significant lagere sterfte en 
cardiovasculaire sterfte tussen patiënten die wel en niet met statines werden 
behandeld. Na correctie voor klinische risicofactoren en het gebruik van bèta-
blokkers, bleef de associatie tussen het gebruik van statines en verminderde sterfte 
(hazard ratio: 0.4, 95% CI, 0.3-0.6) en cardiovasculaire sterfte (hazard ratio: 0.3, 95% 
CI, 0.2-0.6)  bestaan. Op basis hiervan lijkt het dan ook gerechtvaardigd om 
langdurig gebruik van statines te overwegen bij patiënten die geopereerd zijn aan 
een abdominalis aorta aneurisma. 
 
 Tot slot kan worden geconcludeerd dat peri-operatieve en lange termijn 
cardiale risico inschatting en behandeling van patiënten die een grote vaatoperatie 
ondergaan één van de meest uitdagende en controversiële terreinen is binnen de 
klinische geneeskunde. Door middel van ons onderzoek hebben we laten zien dat 
wanneer gebruik gemaakt wordt van geschikte onderzoeksmethoden voor pre-
operatieve risicostratificatie en gebruik gemaakt wordt van peri-operatieve en lange 
termijn risicoreductie strategieën, patiënten niet alleen veilig geopereerd kunnen 
worden, maar hier ook op de korte en op de lange termijn van kunnen profiteren. 
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